The NH-BMT and Leukemia Programs are committed to publishing in the fields of blood and marrow transplantation, leukemia, and hematologic malignancies. The following publications and presentations demonstrate this commitment.

Peer Reviewed Publications

Solh M, Aubrey MT, Zhang X, Bashey A, Freed BM, Roark CL, Bachier-Rdriguez L, Morris LE, Kent Holland H, Solomon SR., HLA evolutionary divergence (HED) informs the effect of HLA-B mismatch on outcomes after haploidentical transplantation, Bone Marrow Transplant, 2024 Oct;59(10):1433-1439. doi: 10.1038/s41409-024-02341-z.

Solomon SR, Bachier-Rodriguez L, Bashey A, Zhang X, Jackson KC, Holland HK, Morris LE, Solh MM., Impact of Graft-Versus-Host Disease on Relapse and Nonrelapse Mortality Following Posttransplant Cyclophosphamide-Based Transplantation,Transplant Cell Theraphy, 2024 Sep;30(9):903.e1-903.e9. doi: 10.1016/j.jtct.2024.06.015.

Farhadfar N, Rashid N, Chen K, DeVos J, Wang T, Ballen K, Beitinjaneh A, Bhatt VR, Hamilton BK, Hematti P, Gadalla SM, Solomon SR, El Jurdi N, Lee CJ, MacMillan ML, Rangarajan HG, Schoemans H, Sharma A, Spellman SR, Wingard JR, Lee SJ., Racial, ethnic, and socioeconomic diversity and outcomes of patients with graft-versus-host disease: a CIBMTR analysis, Blood Advances, 2024 Sep 24;8(18):4963-4976. doi: 10.1182/bloodadvances.

Bashey SZ, Solomon SR, Zhang X, Morris LE, Holland HK, Bachier L, Patel K, Solh MM., Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity, Bone Marrow Transplant, 2024 Sep 19. doi: 10.1038/s41409-024-02417-w.

Dehn JG, Logan B, Shaw BE, Devine S, Ciurea SO, Horowitz M, He N, Pusic I, Srour SA, Arai S, Juckett M, Uberti J, Hill L, Vasu S, Hogan WJ, Hayes-Lattin B, Westervelt P, Bashey A, Farhadfar N, Grunwald MR, Leifer E, Symons H, Saad A, Vogel J, Erickson C, Buck K, Lee SJ, Pidala J., Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional Trial, medRxiv [Preprint]. 2024 Sep 16:2024.09.16.24313494. doi: 10.1101/2024.09.

Kongtim P, Vittayawacharin P, Zou J, Srour S, Shaffer B, Shapiro RM, Varma A, McGuirk J, Dholaria BR, McCurdy SR, DeZern AE, Bejanyan N, Bashey A, Furst S, Castagna L, Mariotti J, Ruggeri A, Bailen R, Teshima T, Xiao-Jun H, Bonfim C, Aung F, Cao K, Carpenter PA, Hamadani M, Askar M, Fernandez-Vina M, Girnita A, Ciurea SO., ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies,Transplant Cell Ther. 2024 Sep 9:S2666-6367(24)00654-7. doi: 10.1016/j.jtct.2024.09.005.

Mercadal S, Ahn KW, Allbee-Johnson M, Ganguly S, Geethakumari PR, Hong S, Malone A, Murthy H, Pawarode A, Sica AR, Solh M, Ustun C, Shadman M, Sauter CS, Hamadani M, Herrera AF, Lee CJ., Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy, Haematologica, 2024 Sep 5. doi: 10.3324/haematol.2024.285613.

Ailawadhi S, Arnulf B, Patel KK, Cavo M, Nooka AK, Manier S, Callander NS, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Abrahamsen IW, Baz RC, Broijl A, Chen C, Jagannath S, Raje N, Scheid C, Delforge M, Benjamin R, Pabst T, Iida S, Berdeja JG, Giralt SA, Truppel-Hartmann A, Chen Y, Zhong X, Wu F, Piasecki J, Eliason L, Dhanda DS, Felten J, Caia A, Cook M, Popa-Mckiver M, Rodriguez-Otero P., Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses, Blood, 2024 Aug 28:blood.2024024582. doi: 1182/blood.2024024582.

Jain T, Estrada-Merly N, Salas MQ, Kim S, DeVos J, Chen M, Fang X, Kumar R, Andrade-Campos M, Elmariah H, Agrawal V, Aljurf M, Bacher U, Badar T, Badawy SM, Ballen K, Beitinjaneh A, Bhatt VR, Bredeson C, DeFilipp Z, Dholaria B, Farhadfar N, Farhan S, Gandhi AP, Ganguly S, Gergis U, Grunwald MR, Hamad N, Hamilton BK, Inamoto Y, Iqbal M, Jamy O, Juckett M, Kharfan-Dabaja MA, Krem MM, Lad DP, Liesveld J, Al Malki MM, Malone AK, Murthy HS, Ortí G, Patel SS, Pawarode A, Perales MA, van der Poel M, Ringden O, Rizzieri DA, Rovó A, Savani BN, Savoie ML, Seo S, Solh M, Ustun C, Verdonck LF, Wingard JR, Wirk B, Bejanyan N, Jones RJ, Nishihori T, Oran B, Nakamura R, Scott B, Saber W, Gupta V., Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study, Blood Advances, 2024 Aug 27;8(16):4281-4293. doi: 10.1182/bloodadvances.

Aldoss I, Roloff GW, Faramand RG, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis YK, Zhang A, Miller K, Sutherland KC, Dykes KC, Ahmed M, Chen EC, Zambrano H, Bradshaw D, Mercadal S, Schwartz MS, Tracy SI, Dholaria B, Kubiak MJ, Mukherjee A, Majhail NS, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy PJ, Logan A, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine JP, Solh MM, Lee CJ, Kota V, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat VA, Shah BD, Muffly L., Impact of Prior Inotuzumab Ozogamicin Treatment on Brexucabtagene Autoleucel outcomes in Adults with B-cell ALL, Blood Advances, 2024 Aug 2:bloodadvances.2024013747. doi: 10.1182/bloodadvances.

Solh M, Bashey A, Zhang X, Holland HK, Bachier-Rdriguez L, Morris LE, Solomon SR., Immunosuppression-Free Status at 1 Year after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide, Transplant Cell Therapy, 2024 Jun;30(6):607.e1-607.e8. doi: 10.1016/j.jtct.2024.03.025.

Solomon SR, Aubrey MT, Bachier-Rodriguez L, Solh MM, Jackson KC, Zhang X, Roark CL, Holland HK, Morris LE, Bashey A., Revised HLA-DP TCE-Core Permissiveness Model Better Defines Relapse Risk and Survival following Haploidentical Transplant,Transplant Cell Therapy, 2024 Jun;30(6):608.e1-608.e10. doi: 10.1016/j.jtct.2024.03.027.

Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators, Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3, Clin Oncology. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474.

Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S., Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma, Future Oncology, 2024;20(18):1221-1235. doi: 10.2217/fon-2023-0954.

Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C., Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study, Haematologica. 2024 Apr 1;109(4):1184-1193. doi: 10.3324/haematol.2023.283459.PMID: 37646659

Wang M, Siddiqi T, Gordon LI, Kamdar M, Lunning M, Hirayama AV, Abramson JS, Arnason J, Ghosh N, Mehta A, Andreadis C, Solomon SR, Kostic A, Dehner C, Espinola R, Peng L, Ogasawara K, Chattin A, Eliason L, Palomba ML, Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study, Journal of Clinical Oncology, 2024 Apr 1;42(10):1146-1157. doi: 10.1200/JCO.23.02214.

Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M., Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen, Future Oncology, 2024;20(21):1455-1465. doi: 10.2217/fon-2023-0898. Epub 2024 Mar 28.PMID: 38547003

Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators, Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3, Journal of Clinical Oncology, 2024 Mar 12: JCO2302474. doi: 10.1200/JCO.23.02474.

McCarthy PL, Attwood KM, Liu X, Chen GL, Minderman H, Alousi A, Bashey A, Lowsky R, Miklos DB, Hansen J, Westervelt P, Yanik G, Waller EK, Howard A, Blazar BR, Wallace PK, Reshef R, Horowitz MM, Maziarz RT, Levine JE, Mohammadpour H., Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study, Bone Marrow Transplant, 2024 Mar;59(3):334-343. doi: 10.1038/s41409-023-02168-0.

Solomon SR, Powell BL, Koprivnikar J, Lai C, Male H, Michaelis LC, Newell LF, Sanford D, Jenkins J, Zelaya A, Coppola S, Faderl S, Walter RB., CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial, Cancers (Basel), 2024 Feb 24;16(5):915. doi: 10.3390

Abramson JS, Palomba ML, Gordon LI, Lunning M, Wang M, Arnason J, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Dehner C, Kim Y, Ogasawara K, Kostic A, Siddiqi T., Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001, Blood, 2024 Feb 1;143(5):404-416. doi: 10.1182.

Bashey SZ, Solomon SR, Zhang X, Morris LE, Kent Holland H, Bachier L, Solh MM., Letermovir prophylaxis lowers the incidence of Non-CMV infections after allogeneic hematopoietic cell transplantation, Bone Marrow Transplant, 2024 Jan 23. doi: 10.1038/s41409-024-02201

Hamadani M, Spira A, Zhou X, Liao L, Chen L, Radford J, Ai W, Solh M, Ardeshna KM, Hess B, Caimi PF, Stathis A, Carlo-Stella C, Alderuccio JP, Kahl B, Wang Y, Qin Y, Xu ZC, Zinzani PL., Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial, Blood Advances, 2024 Jan 9;8(1):93-98. doi: 10.1182.

Alderuccio JP, Reis IM, Hamadani M, Nachiappan M, Leslom S, Kahl BS, Ai WZ, Radford J, Solh M, Ardeshna KM, Hess BT, Lunning MA, Zinzani PL, Stathis A, Carlo-Stella C, Lossos IS, Caimi PF, Han S, Yang F, Kuker RA, Moskowitz CH., PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial, Clinical Cancer Research., 2024 Jan 5;30(1):139-149. doi: 10.1158/1078-0432.CCR-23-1561.

Wang M, Siddiqi T, Gordon LI, Kamdar M, Lunning M, Hirayama AV, Abramson JS, Arnason J, Ghosh N, Mehta A, Andreadis C, Solomon SR, Kostic A, Dehner C, Espinola R, Peng L, Ogasawara K, Chattin A, Eliason L, Palomba ML., Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study, Journal of Clinical Oncology, 2023 Dec 10:JCO2302214. doi: 10.1200/JCO.23.02214.

Jain T, Tsai HL, Elmariah H, Vachhani P, Karantanos T, Wall SA, Gondek LP, Bashey A, Keyzner A, Tamari R, Grunwald MR, Abedin S, Nadiminti KV, Iqbal M, Gerds AT, Viswabandya A, McCurdy SR, Al Malki MM, Varadhan R, Ali H, Gupta V, Jones RJ, Otoukesh S., Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration, Haematologica, 2023 Dec 1;108(12):3321-3332. doi: 10.3324/haematol.2023.283426.

Murthy HS, Zhang MJ, Chen K, Ahmed S, Deotare U, Ganguly S, Kansagra A, Michelis FV, Nishihori T, Patnaik M, Abid MB, Aljurf M, Arai Y, Bacher U, Badar T, Badawy SM, Ballen K, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Brown VI, Martino R, Cahn JY, Castillo P, Cerny J, Chhabra S, Copelan E, Daly A, Dholaria B, Diaz Perez MA, Freytes CO, Grunwald MR, Hashmi S, Hildebrandt GC, Jamy O, Joseph J, Kanakry CG, Khera N, Krem MM, Kuwatsuka Y, Lazarus HM, Lekakis LJ, Liu H, Modi D, Munshi PN, Mussetti A, Palmisiano N, Patel SS, Rizzieri DA, Seo S, Shah MV, Sharma A, Sohl M, Solomon SR, Ulrickson M, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wang T, Wirk B, Zeidan A, Litzow M, Kebriaei P, Hourigan CS, Weisdorf DJ, Saber W, Kharfan-Dabaja MA., Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis, Blood Advances, 2023 Nov 28;7(22):7007-7016. doi: 10.1182/bloodadvances.2023011308.

Ravandi F, Bashey A, Foran J, Stock W, Mawad R, Short N, Yilmaz M, Kantarjian H, Odenike O, Patel A, Garcha R, Ainsworth WB, Clynes R, Kanodia J, Ding Y, Li H, Kye S, Mims A., Phase 1 study of vibecotamab identifies and optimized dose for treatment of relapsed/refractory acute myeloid leukemia, Blood Advances, 2023 Nov 14;7(21):6492-6505. doi: 10.1182/bloodadvances.2023010956.

Murthy HS, Zhang MJ, Chen K, Ahmed S, Deotare U, Ganguly S, Kansagra A, Michelis FV, Nishihori T, Patnaik MM, Abid MB, Aljurf M, Arai Y, Bacher U, Badar T, Badawy SM, Ballen K, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Brown VI, Martino R, Cahn JY, Castillo P, Cerny J, Chhabra S, Copelan EA, Daly A, Dholaria B, Diaz MA, Freytes CO, Grunwald MR, Hashmi S, Hildebrandt GC, Jamy O, Joseph J, Kanakry CG, Khera N, Krem MM, Kuwatsuka Y, Lazarus HM, Lekakis LJ, Liu H, Modi D, Munshi P, Mussetti A, Palmisiano N, Patel SS, Rizzieri DA, Seo S, Shah MV, Sharma A, Solh MM, Solomon SR, Ulrickson ML, Ustun C, van der Poel MWM, Verdonck LF, Wagner JL, Wang TP, Wirk B, Zeidan AM, Litzow MR, Kebriaei P, Hourigan CS, Weisdorf DJ, Saber W, Kharfan-Dabaja MA., Allogeneic Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: A CIBMTR Analysis, Blood Advances, 2023 Oct 4:2023011308. doi: 10.1182/bloodadvances, 2023011308. Online ahead of print.

Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, Tomasson MH, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Gasparetto C, Chu MP, Dalovisio A, Sebag M, Lesokhin AM., Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial, Nat Med., 2023 Oct 2. doi: 10.1038/s41591-023-02589-w Online ahead of print.

Crees ZD, Rettig MP, Bashey A, Devine SM, Jaglowski S, Wan F, Zhou A, Harding M, Vainstein-Haras A, Sorani E, Gliko-Kabir I, Grossman BJ, Westervelt P, DiPersio JF, Uy GL., Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor, Blood Advances, 2023 Sep 26;7(18):5210–5214.

Solomon SR, Solh M, Morris LE, Holland HK, Bachier-Rodriguez L, Zhang X, Guzowski C, Jackson KC, Brown S, Bashey A., Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant, Blood Advances, 2023 Sep 26;7(18):5215–52224.

Ravandi F, Bashey A, Foran JM, Stock W, Mawad R, Short NJ, Yilmaz M, Kantarjian HM, Odenike O, Patel AA, Garcha R, Ainsworth WB, Clynes R, Kanodia J, Ding Y, Li H, Kye S, Mims AS., Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia, Blood Advances, 2023 Aug 30: bloodadvances.2023010956. doi: 10.1182/blood advances.2023010956. Online ahead of print.

Bashey A, Zhang X, Morris LE, Holland HK, Bachier-Rodriguez L, Solomon SR, Solh M., Improved access to HCT
with reduced racial disparities through integration with leukemia care and haploidentical donors, Blood Advances, 2023 Aug 8;7(15):3816-3823. doi: 10.1182/bloodadvances.2023009765.

Tamari R, McLornan DP, Ahn KW, Estrada-Merly N, Hernandez-Boluda JC, Giralt SA, Palmer JM, Gale RP, DeFilipp Z, Marks D, van der Poel MWM, Verdonck LF, Battiwalla M, Díaz MA, Gupta V, Ali H, Litzow MR, Lazarus HM, Gergis U, Bashey A, Liesveld JL, Hashmi S, Pu JJ, Beitinjaneh A, Bredeson CN, Rizzieri DA, Savani BN, Abid MB, Ganguly S, Agrawal V, Ulrike V, Wirk B, Jain T, Cutler CS, Aljurf M, Kindwall-Keller T, Kharfan-Dabaja MA, Hildebrandt GC, Pawarode A, Solh MM, Yared JA, Grunwald MR, Nathan S, Nishihori T, Seo S, Scott BL, Nakamura R, Oran B, Czerw T, Yakoub-Agha I, Saber W., A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis, Blood Advances, 2023 Aug 8;7(15):3993-4002.

Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, Kumar S, Qazilbash MH, Shah N, D'Souza A, Sidana S., Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma, Cancer, 2023 Jul 15;129(14):2179-2191.

Jain T, Tsai HL, Elmariah H, Vachhani P, Karantanos T, Wall SA, Gondek LP, Bashey A, Keyzner A, Tamari R, Grunwald MR, Abedin S, Nadiminti KV, Iqbal M, Gerds AT, Viswabandya A, McCurdy SR, Al Malki MM, Varadhan R, Ali H, Gupta V, Jones RJ, Otoukesh S., Haploidenital donor hemotopoetic cell transplantion for myelodysplastic/myeloproliferative overlap
neoplasms: results from a North American collaboration, Haematologica, 2023 Jul 6. doi: 10.3324/haematol, 2023.283426. Online ahead of print.

Murthy GSG, Kim S, Estrada-Merly N, Abid MB, Aljurf M, Assal A, Badar T, Badawy SM, Ballen K, Beitinjaneh A, Cerny J, Chhabra S, DeFilipp Z, Dholaria B, Perez MAD, Farhan S, Freytes CO, Gale RP, Ganguly S, Gupta V, Grunwald MR, Hamad N, Hildebrandt GC, Inamoto Y, Jain T, Jamy O, Juckett M, Kalaycio M, Krem MM, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Ortí G, Patel SS, Van der Poel M, Rizzieri DA, Savani BN, Seo S, Solh M, Verdonck LF, Wirk B, Yared JA, Nakamura R, Oran B, Scott B, Saber W., Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis, Haematologica, 2023 Jul 1;108(7):1900-1908.

Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse C, Badawy SM, Al Hadidi S, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh M, Munshi PN, Nishihori T, Anderson LD Jr, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ., Impact of second primary malignancy post-autologous transplantion on outcomes of multiple myeloma: a CIBMTR analysis, Blood Advances, 2023 Jun 27;7(12):2746–2757. doi: 10.1182/bloodadvances.2022009138.

Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG; BMT CTN 1703 Investigators, Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis, New England Journal of Medicine, 2023 Jun 22;388(25):2338-2348.

Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG., Lisocabtagene maraleucel in chronic lymphocytic leukemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study, Lancet, 2023 Jun 5: S0140-6736(23)01052-8.

Boyiadzis M, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Bacher U, Badar T, Badawy SM, Battiwalla M, Bejanyan N, Bhatt VR, Brown VI, Castillo P, Cerny J, Copelan EA, Craddock C, Dholaria B, Perez MAD, Ebens CL, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt GC, Iqbal M, Jamy O, Kharfan-Dabaja MA, Khera N, Lazarus HM, Lin R, Modi D, Nathan S, Nishihori T, Patel SS, Pawarode A, Saber W, Sharma A, Solh M, Wagner JL, Wang T, Williams KM, Winestone LE, Wirk B, Zeidan A, Hourigan CS, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf DJ., Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients, Leukemia, 2023 May;37(5):1173.

Garcia JS, Flamand Y, Penter L, Keng M, Tomlinson BK, Mendez LM, Koller P, Cullen N, Arihara Y, Pfaff K, Wolff JO, Brunner AM, Galinsky I, Bashey A, Antin JH, Cutler C, Ho V, Jonas BA, Luskin MR, Wadleigh M, Winer ES, Savell A, Leonard R, Robertson T, Davids MS, Streicher H, Rodig SJ, Ritz J, Wu CJ, DeAngelo DJ, Neuberg D, Stone RM, Soiffer RJ., Ipilimumab plus decitabine for patients with MDS or AML in post transplant or transplant-naïve settings, Blood, 2023 Apr 13;141(15):1884-1888.

Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M., Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study, Blood. 2023 Apr 6;141(14):1675-1684.

Jain T, Tsai HL, Elmariah H, Vachhani P, Karantanos T, Wall S, Gondek L, Bashey A, Keyzner A, Tamari R, Grunwald M, Abedin S, Nadiminti K, Iqbal M, Gerds A, Viswabandya A, McCurdy S, Malki MA, Varadhan R, Ali H, Gupta V, Jones RJ, Otoukesh S., Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration, Res Sq. 2023 Mar 21:rs.3.rs-2691216.

Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S., Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma, N Engl J Med., 2023 Mar 16;388(11):1002-1014.

DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, Brunner AM, Dholaria B, Walker AR, Kröger N, Bejanyan N, Atallah E, Tamari R, Solh MM, Percival ME, de Lima M, Scott B, Oran B, Garcia-Manero G, Hamadani M, Carpenter P, DeZern AE., Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines,Transplant Cell Ther. 2023 Feb;29(2):71-81.

Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, DeLima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse CS, Badawy SM, Al Hadidi SA, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh MM, Munshi P, Nishihori T, Anderson LD Jr, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ., Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis, Blood Adv. 2023 Feb 24.

Solh MM, Farnham C, Solomon SR, Bashey A, Morris LE, Holland HK, Zhang X., Extracorporeal photopheresis (ECP) improves overall survival in the treatment of steroid refractory acute graft-versus-host disease (SR aGvHD), Bone Marrow Transplant. 2023 Feb;58(2):168-174.

D'Souza A, Brazauskas R, Stadtmauer EA, Pasquini MC, Hari P, Bashey A, Callander N, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Landau H, Brunstein C, McCarthy P, Qazilbash MH, Giralt S, Krishnan A, Flynn KE., Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma, Am J Hematol. 2023 Jan;98(1):140-147.

Mei M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, Meng Z, Abid MB, Aljurf M, Bacher U, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Copelan E, Cutler C, DeFilipp Z, Diaz Perez MA, Farhadfar N, Freytes CO, Gadalla SM, Ganguly S, Gale RP, Gergis U, Grunwald MR, Hamilton BK, Hashmi S, Hildebrandt GC, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Patel SS, Rizzieri D, Seo S, Shah MV, Solh M, Verdonck LF, Vij R, Sobecks RM, Oran B, Scott BL, Saber W, Nakamura R., The mutational landscape in chronic myelomonocytic leukemia and its impact on Allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis, Haematologica, 2023 Jan 1;108(1):150-160.

Zhang X, Solomon SR, Sizemore C., Inferences for current chronic graft-versus-host-disease free and relapse free survival, BMC Med Res Methodol. 2022 Dec 13;22(1):318.

Abramson JS, Johnston PB, Kamdar M, Ibrahimi S, Izutsu K, Arnason JE, Glass B, Mutsaers PGNJ, Lunning M, Braverman J, Liu FF, Crotta A, Montheard S, Previtali A, Guo S, Shi L, Solomon SR., Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL, Blood Advances, 2022 Sep 23: loodadvances.2022008106.

DeZern AE, Eapen M, Wu J, Talano JA, Solh M, Dávila Saldaña BJ, Karanes C, Horwitz ME, Mallhi K, Arai S, Farhadfar N, Hexner E, Westervelt P, Antin JH, Deeg HJ, Leifer E, Brodsky RA, Logan BR, Horowitz MM, Jones RJ, Pulsipher MA, Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial, Lancet Hematology, 2022 Sep;9(9):e660-e669.

Solomon SR, Brown S, Shegda N, Jackson KC, Zhang X, Bashey A, Holland HK, Morris LE, Solh M., High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma, Transplant Cell Therapy. 2022 Aug;28(8): 486.e1-486.e7.

Alderuccio JP, Ai WZ, Radford J, Solh M, Ardeshna KM, Lunning MA, Hess BT, Zinzani PL, Stathis A, Carlo-Stella C, Hamadani M, Kahl BS, Ungar D, Kilavuz T, Yu E, Qin Y, Caimi PF., Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study, Blood Advances, 2022 Aug 23;6(16):4736-4739.

Brunstein CG, O'Donnell PV, Logan B, Dawson P, Costa L, Cutler C, Craig M, Hogan W, Horowitz MM, Horwitz ME, Karanes C, Magenau JM, Malone A, McCarty J, McGuirk JP, Morris LE, Rezvani AR, Salit R, Vasu S, Eapen M, Fuchs EJ; Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101 Open for Accrual June 2012 Open for Accrual June 2012, Blood and Marrow Transplant Clinical Trials Network, Transplant Cell Therapy, 2022 Jul;28(7):406.e1-406.e6.

Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, Bredeson CN, Brunstein CG, Chhabra S, Fuchs EJ, Ghosh N, Grunwald MR, Kanakry CG, Kekre N, McGuirk JP, McNiece IK, Mehta RS, Mielcarek M, Milano F, Modi D, Reshef R, Solomon SR, Schroeder MA, Waller EK, Inamoto Y, Soiffer RJ, Eapen M., HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis, Blood,2021 Jul 22;138(3):273-282.

Alderuccio JP, Ai WZ, Radford J, Solh MM, Ardeshna KM, Lunning M, Hess B, Luigi Zinzani P, Stathis A, Carlo Stella C, Hamadani M, Kahl BS, Ungar D, Kilavuz T, Yu E, Qin YG, Caimi PF., Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study, Blood Advances, 2022 Jul.

Solomon SR, Aubrey MT, Zhang X, Jackson KC, Roark CL, Freed BM, Morris LE, HollandHK, Solh MM, Bashey A., Lineage-Specific Relapse Prediction Following Haploidentical Transplant with Post-Transplant Cyclophosphamide Based on Recipient HLA-B-Leader Genotype and HLA-C-Group KIR Ligand, Transplant Cell Therapy, 2022 Jul 1: S2666-6367(22)01432-4.

Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS, Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomized, phase 3 trial, Lancet, 2022 Jun 18;399(10343):2294-2308.

Caimi PF, Ardeshna KM, Reid E, Ai W, Lunning M, Zain J, Solh M, Kahl BS, Hamadani M., The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy, Clinical Lymphoma Myeloma Leukemia, 2022 May;22(5):e335-e339.

Solomon SR, Brown S, Shegda N, Jackson KC, Zhang X, Bashey A, Holland HK, Morris LE, Solh M., High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma, Transplant Cellular Therapy, 2022 May 20:S2666-6367(22)01313-6.

Jimenez Jimenez AM, De Lima M, Komanduri KV, Wang TP, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Alkhateeb H, Assal A, Bacher U, Baron F, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Copelan E, DeFilipp Z, Perez MAD, Elsawy M, Gale RP, George B, Grunwald MR, Hildebrandt GC, Hogan WJ, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Khera N, Krem MM, Lazaryan A, Maakaron J, Martino R, McGuirk J, Michelis FV, Milone G, Mishra A, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Patel S, Saad A, Seo S, Sharma A, Solh M, Verdonck LF, Wirk B, Yared JA, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D., Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic transplant. A CIBMTR anaylsis, Bone Marrow Transplant, 2022 May;57(5):852.

Mei M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, Meng Z, Abid MB, Aljurf M, Bacher U, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Copelan E, Cutler C, DeFilipp Z, Diaz Perez MA, Farhadfar N, Freytes CO, Gadalla SM, Ganguly S, Gale RP, Gergis U, Grunwald MR, Hamilton BK, Hashmi S, Hildebrandt GC, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Patel SS, Rizzieri D, Seo S, Shah MV, Solh M, Verdonck LF, Vij R, Sobecks RM, Oran B, Scott BL, Saber W, Nakamura R., The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis, Haematologica, 2022 Apr 21.

Fuchs EJ, McCurdy SR, Solomon SR, Wang T, Herr MR, Modi D, Grunwald MR, Nishihori T, Kuxhausen M, Fingerson S, McKallor C, Bashey A, Kasamon YL, Bolon YT, Saad A, McGuirk J, Paczesny S, Gadalla SM, Marsh SGE, Shaw BE, Spellman SR, Lee SJ, Petersdorf EW, HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide, Blood, 2022 Mar 10;139(10):1452-1468.

Guru Murthy GS, Kim S, Hu ZH, Estrada-Merly N, Abid MB, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Diaz Perez MA, Farhadfar N, Gale RP, Ganguly S, Gergis U, Hildebrandt GC, Grunwald MR, Hashmi S, Hossain NM, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Hamilton BK, Lazarus HM, Liesveld J, Litzow M, Marks DI, Murthy HS, Nathan S, Nazha A, Nishihori T, Patel SS, Pawarode A, Rizzieri D, Savani B, Seo S, Solh M, Ustun C, van der Poel M, Verdonck LF, Vij R, Wirk B, Oran B, Nakamura R, Scott B, Saber W., Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors, JAMA Oncology, 2022 Mar 1;8(3):404-411.

Kunte S, Rybicki L, Viswabandya A, Tamari R, Bashey A, Keyzner A, Iqbal M, Grunwald MR, Dholaria B, Elmariah H, Ozga M, Singh A, Abedin S, DeZern AE, Jones RJ, Gupta V, Gerds AT, Jain T., Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study, Leukemia, 2022 Mar;36(3):856-864.

Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD Jr, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D'Souza A., Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation, Transplant Cell Therapy, 2022 Feb;28(2):83.e1-83.e9.

O'Donnell PV, Brunstein CG, Fuchs EJ, Zhang MJ, Allbee-Johnson M, Antin JH, Leifer ES, Elmariah H, Grunwald MR, Hashmi H, Horowitz MM, Magenau JM, Majhail N, Milano F, Morris LE, Rezvani AR, McGuirk JP, Jones RJ, Eapen M., Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes,Transplant Cellular Therapy, Transplant Cell Ther. 2022 Feb;28(2): 109.e1–109.e8.

Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, Horowitz MM, Jones RJ, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O'Donnell L, O'Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA., Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies, Journal of Clinical Oncology, 2022 Feb 1;40(4):356-368.

Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao N, Rizzieri D, Gale RP, Gadalla SM, Cairo M, Mussetti A, Gore S, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson C, Diaz Perez MA, Cassaday R, Savani BN, Ballen K, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel MD, van der Poel M, Grunwald MR, Liesveld JL, Kamble RT, McGuirk J, Munker R, Cahn JY, Lee JW, Freytes CO, Krem MM, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringdén O, Friend BD, Cerny J, Choe H, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, Litzow M, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W, Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia, Blood Advances, 2022 Jan 11;6(1):339-357.

Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang MJ, Bo-Subait K, Sanchez J, Wang HL, Aljurf M, Assal A, Bacher VU, Badawy SM, Bejanyan N, Bhatt VR, Bredeson C, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla S, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt G, Kanakry CG, Kansagra A, Khimani F, Krem M, Lazarus H, Liu H, Martino R, Michelis FV, Nathan S, Nishihori T, Olsson R, Reshef R, Rizzieri D, Rowe JM, Savani BN, Seo S, Sharma A, Solh M, Ustun C, Verdonck LF, Hourigan C, Sandmaier B, Litzow M, Kebriaei P, Weisdorf D, Zhang Y, Tallman MS, Saber W., Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML, Blood Advances, 2022 Jan 8;6(3):828-847.

Brunstein CG, O'Donnell PV, Logan B, Dawson P, Costa L, Cutler C, Craig M, Hogan W, Horowitz MM, Horwitz ME, Karanes C, Magenau JM, Malone A, McCarty J, McGuirk JP, Morris LE, Rezvani AR, Salit R, Vasu S, Eapen M, Fuchs EJ; Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012, Blood and Marrow Transplant Clinical Trials Network, Transplant Cell Therapy, 2022 Jul;28(7):406.e1-406.e6.

Solomon SR, Aubrey MT, Zhang X, Jackson KC, Roark CL, Freed BM, Morris LE, HollandHK, Solh MM, Bashey A., Lineage-Specific Relapse Prediction Following Haploidentical Transplant with Post-Transplant Cyclophosphamide Based on Recipient HLA-B-Leader Genotype and HLA-C-Group KIR Ligand, Transplant Cell Therapy, 2022 Jul 1:S2666-6367(22)01432-4.

Solomon SR, Brown S, Shegda N, Jackson KC, Zhang X, Bashey A, Holland HK, Morris LE, Solh M., High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma, Transplant Cellular Therapy, 2022 May 20:S2666-6367(22)01313-6.

Jimenez Jimenez AM, De Lima M, Komanduri KV, Wang TP, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Alkhateeb H, Assal A, Bacher U, Baron F, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Copelan E, DeFilipp Z, Perez MAD, Elsawy M, Gale RP, George B, Grunwald MR, Hildebrandt GC, Hogan WJ, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Khera N, Krem MM, Lazaryan A, Maakaron J, Martino R, McGuirk J, Michelis FV, Milone G, Mishra A, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Patel S, Saad A, Seo S, Sharma A, Solh M, Verdonck LF, Wirk B, Yared JA, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D., Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis, Bone Marrow Transplant, 2022 May;57(5):852.

Mei M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, Meng Z, Abid MB, Aljurf M, Bacher U, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Copelan E, Cutler C, DeFilipp Z, Diaz Perez MA, Farhadfar N, Freytes CO, Gadalla SM, Ganguly S, Gale RP, Gergis U, Grunwald MR, Hamilton BK, Hashmi S, Hildebrandt GC, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Patel SS, Rizzieri D, Seo S, Shah MV, Solh M, Verdonck LF, Vij R, Sobecks RM, Oran B, Scott BL, Saber W, Nakamura R., The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis, Haematologica, 2022 Apr 21.

Fuchs EJ, McCurdy SR, Solomon SR, Wang T, Herr MR, Modi D, Grunwald MR, Nishihori T, Kuxhausen M, Fingerson S, McKallor C, Bashey A, Kasamon YL, Bolon YT, Saad A, McGuirk J, Paczesny S, Gadalla SM, Marsh SGE, Shaw BE, Spellman SR, Lee SJ, Petersdorf EW, HLA informs risk predictions after haploidentical stem cell transplantation with post transplantation cyclophosphamide, Blood, 2022 Mar 10;139(10):1452-1468.

Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, Horowitz MM, Jones RJ, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O'Donnell L, O'Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA., Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies, Journel of Clinical Oncology, 2022 Feb 1;40(4):356-368.

Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao N, Rizzieri D, Gale RP, Gadalla SM, Cairo M, Mussetti A, Gore S, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson C, Diaz Perez MA, Cassaday R, Savani BN, Ballen K, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel MD, van der Poel M, Grunwald MR, Liesveld JL, Kamble RT, McGuirk J, Munker R, Cahn JY, Lee JW, Freytes CO, Krem MM, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringdén O, Friend BD, Cerny J, Choe H, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, Litzow M, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W, Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia, Blood Advances, 2022 Jan 11;6(1):339-357.

Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao NJ, Rizzieri D, Gale RP, Gadalla SM, Cairo MS, Mussetti A, Gore SD, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson CN, Diaz Perez MA, Cassaday R, Savani BN, Ballen KK, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel M, van der Poel MWM, Grunwald MR, Liesveld JL, Kamble RT, McGuirk JP, Munker R, Cahn JY, Lee JW, Freytes CO, Krem M, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringden O, Friend BD, Cerny J, Choe HK, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, Litzow MR, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W., Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia, Blood Advances,2022 Jan 11;6(1):339-357.

Orfali N, Zhang MJ, Allbee-Johnson M, Boelens JJ, Artz AS, Brunstein CG, McNiece IK, Milano F, Abid MB, Chee L, Diaz MA, Grunwald MR, Hematti P, Hsu J, Lazarus HM, Munshi PN, Prestidge T, Ringden O, Rizzieri D, Riches ML, Seo S, Solh M, Solomon S, Szwajcer D, Yared J, van Besien K, Eapen M., Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy, Transplant Cell Therapy, 2021 Dec;27(12):993.e1-993.e8.

Jimenez Jimenez AM, De Lima M, Komanduri KV, Wang TP, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Alkhateeb H, Assal A, Bacher U, Baron F, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Copelan E, DeFilipp Z, Perez MAD, Elsawy M, Gale RP, George B, Grunwald MR, Hildebrandt GC, Hogan WJ, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Khera N, Krem MM, Lazaryan A, Maakaron J, Martino R, McGuirk J, Michelis FV, Milone G, Mishra A, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Patel S, Saad A, Seo S, Sharma A, Solh M, Verdonck LF, Wirk B, Yared JA, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D., An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis, Bone Marrow Transplant, 2021 Dec;56(12):3068-3077.

Hess B, Townsend W, Ai W, Stathis A, Solh M, Alderuccio JP, Ungar D, Liao S, Liao L, Khouri L, Zhang X, Boni J., Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma, AAPS J. 2021 Dec 10;24(1):11.

Riedell PA, Hamadani M, Ahn KW, Litovich C, Brunstein CG, Cashen AF, Cohen JB, Epperla N, Hill BT, Im A, Inwards DJ, Lister J, McCarty JM, Ravi Kiran Pingali S, Shadman M, Shaughnessy P, Solh M, Stiff PJ, Vose JM, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM., Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation, British Journel of Haematology. 2021 Dec;195(5):757-763.

Kantarjian HM, Begna KH, Altman JK, Goldberg SL, Sekeres MA, Strickland SA, Arellano ML, Claxton DF, Baer MR, Gautier M, Berman E, Seiter K, Solomon SR, Schiller GJ, Luger SM, Butrym A, Gaidano G, Thomas XG, Montesinos P, Rizzieri DA, Quick DP, Venugopal P, Gaur R, Maness LJ, Kadia TM, Ravandi F, Buyse ME, Chiao JH., Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS), Cancer. 2021 Dec 1;127(23):4421-4431.

Oran B, Ahn KW, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, Wirk B, Scott BL, Savani BN, Bredeson C, Weisdorf D, Marks DI, Rizzieri D, Copelan E, Hildebrandt GC, Hale GA, Murthy HS, Lazarus HM, Cerny J, Liesveld JL, Yared JA, Yves-Cahn J, Szer J, Verdonck LF, Aljurf M, van der Poel M, Litzow M, Kalaycio M, Grunwald MR, Diaz MA, Sabloff M, Kharfan-Dabaja MA, Majhail NS, Farhadfar N, Reshef R, Olsson RF, Gale RP, Nakamura R, Seo S, Chhabra S, Hashmi S, Farhan S, Ganguly S, Nathan S, Nishihori T, Jain T, Agrawal V, Bacher U, Popat U, Saber W., Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes,Transplant Cell Ther. 2021 Nov; 27(11):921.e1-921.e10

Desai PM, Brown J, Gill S, Solh MM, Akard LP, Hsu JW, Ustun C, Andreadis C, Frankfurt O, Foran JM, Lister J, Schiller GJ, Wieduwilt MJ, Pagel JM, Stiff PJ, Liu D, Khan I, Stock W, Kambhampati S, Tallman MS, Morris L, Edwards J, Pusic I, Kantarjian HM, Mamelok R, Wong A, Van Syoc R, Kellerman L, Panuganti S, Mandalam R, Abboud CN, Ravandi F., Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia, Journal of Clinical Oncology. 2021 Oct 10;39(29):3261-3272.

Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang MJ, Bo-Subait K, Sanchez J, Wang HL, Aljurf M, Assal A, Bacher U, Badawy SM, Bejanyan N, Bhatt VR, Bredeson CN, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla SM, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt GC, Kanakry CG, Kansagra A, Khimani F, Krem M, Lazarus HM, Liu H, Martino R, Michelis FV, Nathan S, Nishihori T, Olsson RF, Reshef R, Rizzieri D, Rowe JM, Savani BN, Seo S, Sharma A, Solh M, Ustun C, Verdonck LF, Hourigan CS, Sandmaier BM, Litzow MR, Kebriaei P, Weisdorf DJ, Zhang Y, Tallman MS, Saber W., Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML, Blood Advances. 2021 Sep 22:bloodadvances.2021004881.

Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM., Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation, Bone Marrow Transplant, 2021 Sep;56(9):2319.

Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, Ahmed EH, Schlotter S, Pearson R, Kitzler R, Mozhenkova A, Le-Rademacher J, Little RF, Akpek G, Ayala E, Devine SM, Kaplan LD, Noy A, Popat UR, Hsu JW, Morris LE, Mendizabal AM, Krishnan A, Wachsman W, Williams N, Sharma N, Hofmeister CC, Forman SJ, Navarro WH, Alvarnas JC, Ambinder RF, Lozanski G, Baiocchi RA., Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial, Front Immunology. 2021 Sep 3;12:700045.

Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C., Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma, Leukemia, 2021 Sep;35(9):2672-2683.

Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, Bredeson CN, Brunstein CG, Chhabra S, Fuchs EJ, Ghosh N, Grunwald MR, Kanakry CG, Kekre N, McGuirk JP, McNiece IK, Mehta RS, Mielcarek M, Milano F, Modi D, Reshef R, Solomon SR, Schroeder MA, Waller EK, Inamoto Y, Soiffer RJ, Eapen M. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood, 2021 Jul 22;138(3):273-282.

Mulroney CM, Abid MB, Bashey A, Chemaly RF, Ciurea SO, Chen M, Dandoy CE, Diaz Perez MA, Friend BD, Fuchs E, Ganguly S, Goldsmith SR, Kanakry CG, Kim S, Komanduri KV, Krem MM, Lazarus HM, Ljungman P, Maziarz R, Nishihori T, Patel SS, Perales MA, Romee R, Singh AK, Reid Wingard J, Yared J, Riches M, Taplitz R., Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation, Br J Haematol. 2021 Jul;194(1):145-157.

Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Faderl S, Cortes JE., CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukemia: 5-year results of a randomized, open-label, multicenter, phase 3 trial, Lancet Haematol, 2021 Jul;8(7):e481-e491.

Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A., Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era., Leukemia. 2021 Jul;35(7):2141.

Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS., Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant, JAMA Oncology, 2021 Jul 1;7(7):993-1003.

Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Soiffer RJ, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Hourigan CS, Gui G, Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME.
Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial, Transplant Cell Ther. 2021 Jun;27(6):483.e1-483.e6.

Desai P, Brown J, Gill S, Solh MM, Akard LP, Hsu JW, Ustun C, Andreadis C, Frankfurt O, Foran JM, Lister J, Schiller GJ, Wieduwilt MJ, Pagel JM, Stiff PJ, Liu D, Khan I, Stock W, Kambhampati S, Tallman MS, Morris L, Edwards J, Pusic I, Kantarjian HM, Mamelok R, Wong A, Van Syoc R, Kellerman L, Panuganti S, Mandalam R, Abboud CN, Ravandi F. Open-Label Phase II prospective randomized controlled study of Romyelocel-L myeloid progenitor cells to reduce infection during induction chemotherapy for Acute Myeloid leukemia, Journal of Clinical Oncology, 2021 jun 22.

Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C., Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial, Lancet Oncology, 2021 Jun;22(6):790-800.

Goldsmith SR, Abid MB, Auletta JJ, Bashey A, Beitinjaneh A, Castillo P, Chemaly RF, Chen M, Ciurea S, Dandoy CE, Díaz MÁ, Fuchs E, Ganguly S, Kanakry CG, Kanakry JA, Kim S, Komanduri KV, Krem MM, Lazarus HM, Liu H, Ljungman P, Masiarz R, Mulroney C, Nathan S, Nishihori T, Page KM, Perales MA, Taplitz R, Romee R, Riches M., Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis, Blood, 2021 Jun 10;137(23):3291-3305.

Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A., Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era., Leukemia. 2021 Jun;35(6):1828. doi: 10.1038/s41375-021-01233-1.

Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O'Connor OA, Feingold JM, Ardeshna KM, Townsend W, Solh M, Heffner LT, Ungar D, Wang L, Boni J, Havenith K, Qin Y, Kahl BS., Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma, Blood, 2021 May 13;137(19):2634-2645.

Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M., Correction: Allogeneic transplantation in elderly patients >65 years with non-Hodgkin lymphoma: a time-trend anlysis, Blood Cancer Journal, 2021 Apr 29;11(4):82.

Ferrari V, Tarke A, Fields H, Ferrari L, Conley T, Ferrari F, Koşaloğlu-Yalçın Z, Sette A, Peters B, McCarthy CL, Bashey A, Tzachanis D, Ball ED, Tanaka TN, Bejar R, Lane TA, Vitiello A., In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden, Cytotherapy, 2021 Apr; 23(4):320-328.

Jillella AP, Arellano ML, GadJidh M, Langston AA, Heffner LT, Winton EF, McLemore ML, Zhang C, Caprara CR, Simon KS, Bolds SL, DeBragga S, Karkhanis P, Krishnamurthy SH, Tongol J, El Geneidy MM, Pati A, Gerber JM, Grunwald MR, Cortes J, Bashey A, Stuart RK, Kota VK., Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia, JCO Oncol Pract, 2021 Apr;17(4):e497-e505.

Ercival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM., Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 Apr 16. doi: 10.1038/s41409-021-01261-6. Epub ahead of print. Erratum in: Bone Marrow Transplant, 2021 May 20;: PMID: 33864019.

Gooptu M, Romee R, St Martin A, Arora M, Al Malki MM, Antin JH, Bredeson CN, Brunstein CG, Chhabra S, Fuchs EJ, Ghosh N, Grunwald MR, Kanakry CG, Kekre N, McGuirk JP, McNiece I, Mehta RS, Mielcarek M, Milano F, Modi D, Reshef R, Solomon SR, Schroeder MA, Waller EK, Inamoto Y, Soiffer RJ, Eapen M. HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis, Blood, 2021 Apr 13.

Giza SA, Sethi S, Smith LM, Empey MET, Morris LE, McKenzie CA.J, The application of in utero magnetic resonance imaging in the study of the metabolic and cardiovascular consequences of the developmental origins of health and disease, Dev Orig Health Dis., 2021, Apr:12(2): 193-202.

Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan- Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A., Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era, Leukemia, 2021 Mar 29.

Solh MM, Hinojosa G, Laporte J, Solomon SR, Morris LE, Zhang X, Holland HK, Bashey A., A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T- Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies, Adv Hematol, 2021 Mar 23;2021:8868142.

Lin TL, Rizzieri DA, Ryan DH, Schiller GJ, Kolitz JE, Uy GL, Hogge DE, Solomon SR, Wieduwilt MJ, Ryan RJ, Faderl S, Cortes JE, Lancet JE. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses, Blood Advances, 2021 Mar 23;5(6):1719-1728.

Goldsmith SR, Abid MB, Auletta JJ, Bashey A, Beitinjaneh A, Castillo P, Chemaly RF, Chen M, Ciurea SO, Dandoy CE, Angel Diaz M, Fuchs EJ, Ganguly S, Kanakry CG, Kanakry JA, Kim S, Komanduri K, Krem M, Lazarus HM, Liu H, Ljungman P, Maziarz RT, Mulroney C, Nathan S, Nishihori T, Page KM, Perales MA, Taplitz RA, Romee R, Riches M., Post-Transplant Cyclophosphamide (PTCy) is Associated with increased Cytomegalovirus Infection: A CIBMTR Analysis, Blood, 2021 Mar 3.

Farhadfar N, Dias A, Wang T, Fretham C, Chhabra S, Murthy HS, Broglie L, D'Souza A, Gadalla SM, Gale RP, Hashmi S, Al-Homsi AS, Hildebrandt GC, Hematti P, Rizzieri D, Chee L, Lazarus HM, Bredeson C, Jaimes EA, Beitinjaneh A, Bashey A, Prestidge T, Krem MM, Marks DI, Benoit S, Yared JA, Nishihori T, Olsson RF, Freytes CO, Stadtmauer E, Savani BN, Sorror ML, Ganguly S, Wingard JR, Pasquini M., Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation, Transplant Cell Therapy 2021, Feb 26. S2666-6367(21)00717-X.

Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Soiffer RJ, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Hourigan CS, Gui G, Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME, Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic-Syndromes Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial, Transplant Cell Therapy, 2021 Feb 26. S2666-6367(21)00718-1.

Grunwald MR, Zhang MJ, Elmariah H, Johnson MH, St Martin A, Bashey A, Battiwalla M, Bredeson CN, Copelan E, Cutler CS, George BR, Gupta V, Kanakry C, Mehta RS, Milano F, Mussetti A, Nakamura R, Nishihori T, Saber W, Solh M, Weisdorf DJ, Eapen M., Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors, Blood Adv., 2021 Feb 23;5(4):975-983.

Farhadfar N, Murthy HS, Logan BR, Sees JA, Ayas M, Battiwalla M, Beitinjaneh AM, Chhabra S, Diaz MA, Engles K, Frangoul H, Ganguly S, Gergis U, Kamani NR, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Norkin M, O' Donnell PV, Olsson RF, Rossmann S, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Sugrue M, Yared JA, Linenberger M, Schwartz J, Pulsipher MA, Shah NN, Switzer GE, Confer DL, Shaw BE, Wingard JR., Correction: Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis, Bone Marrow Transplant 2021 Feb;56(2):522.

Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, Dias A, Copelan E, Hale G, Gale RP, Solh M, Kharfan-Dabaja MA, Diaz MA, Ganguly S, Gore S, Verdonck LF, Hossain NM, Kekre N, Savani B, Byrne M, Kanakry C, Cairo MS, Ciurea S, Schouten HC, Bredeson C, Munker R, Lazarus H, Cahn JY, van Der Poel M, Rizzieri D, Yared JA, Freytes C, Cerny J, Aljurf M, Palmisiano ND, Pawarode A, Bacher VU, Grunwald MR, Nathan S, Wirk B, Hildebrandt GC, Seo S, Olsson RF, George B, de Lima M, Hourigan CS, Sandmaier BM, Litzow M, Kebriaei P, Saber W, Weisdorf D., Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study, Transplant Cell Ther. 2021 Jan;27(1):68.e1-68.e9.

Fuchs EJ, O'Donnell PV, Eapen M, Logan B, Antin JH, Dawson P, Devine S, Horowitz MM, Horwitz ME, Karanes C, Leifer E, Magenau JM, McGuirk JP, Morris LE, Rezvani AR, Jones RJ, Brunstein CG., Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial, Blood. 2021 Jan 21;137(3):420-428.

Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Warlick ED, Pasquini MC, Scott BL, Horwitz ME, Deeg HJ, Hourigan CS., Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome, JCO Precis Oncol. 2021 Jan 5;5:PO.20.00355.

Nazha A, Hu ZH, Wang T, Lindsley RC, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn JY, Cerny J, Copelan E, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla SM, Gale RP, George B, Gergis U, Grunwald MR, Hamilton B, Hashmi S, Hildebrandt GC, Inamoto Y, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Liesveld JL, Litzow MR, Majhail NS, Murthy HS, Nathan S, Nishihori T, Pawarode A, Rizzieri D, Sabloff M, Savani BN, Schachter L, Schouten HC, Seo S, Shah NN, Solh M, Valcárcel D, Vij R, Warlick E, Wirk B, Wood WA, Yared JA, Alyea E, Popat U, Sobecks RM, Scott BL, Nakamura R, Saber W., A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes, Biol Blood Marrow Transplant, 2020 Nov;26(11):2139-2146.

Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid EG, O'Connor OA, Feingold J, Ardeshna KM, Townsend WM, Solh M, Heffner LT, Ungar D, Wang L, Boni JP, Havenith K, Qin YG, Kahl B. Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma, Blood, 2020 Nov 19.2020007512.

Solh MM, Baron J, Zhang X, Bashey A, Morris LE, Holland HK, Solomon SR., Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors, Biol Blood Marrow Transplant, 2020 Nov;26(11):2082-2088.

Solomon SR, Aubrey MT, Zhang X, Jackson KC, Morris LE, Holland HK, Solh MM, Bashey A., Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide, Blood Advances, 2020 Oct 27;4(20):5311-532.

Scott R Solomon, Andrew St Martin, Mei-Jie Zhang, Karen Ballen, Asad Bashey, Minoo Battiwalla, Lee Ann Baxter-Lowe, ,Claudio Brunstein, Saurabh Chhabra, Miguel Angel Diaz Perez, Ephraim J Fuchs, Siddhartha Ganguly, Nancy Hardy, Peiman Hematti, Joseph McGuirk, Edward Peres, Olle Ringden, David Rizzieri, Rizwan Romee, Melhem Solh, David Szwajcer, Marjolein van der Poel, Edmund Waller, Basem M William, Mary Eapen, Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant, Biology of Blood and Marrow Transplant, 2020 Oct;26(10):1930-1936.

Ephraim Fuchs, M.D., Paul O’Donnell, M.D., Ph.D., Claudio Brunstein, M.D. Morris LE, Results of Blood and Marrow Transplant Clinical Trials Network Protocol 1101 a Multicenter Phase III Randomized Trial of Transplantation of Double Umbilical Cord Blood Vs. HLA-Haploidentical Related Bone Marrow for Hematologic Malignancy, Biol Blood and Marrow Trans, 2020 in press.

Solh MM, Speckhart D, Solomon SR, Bashey A, Morris LE, Zhang X, Holland HK., The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation, Blood Adv., 2020 Oct 13;4(19):4812-4821.

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T., Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study, Lancet, 2020 Sep 19;396(10254):839-852.

Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, Abdel-Azim H, Agrawal V, Al-Homsi AS, Aljurf M, Askar M, Auletta JJ, Bashey A, Beitinjaneh A, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Cerny J, Chhabra S, Choe H, Ciurea S, Daly A, Perez MAD, Farhadfar N, Gadalla SM, Gale R, Ganguly S, Gergis U, Hanna R, Hematti P, Herzig R, Hildebrandt GC, Lad DP, Lee C, Lehmann L, Lekakis L, Kamble RT, Kharfan-Dabaja MA, Khandelwal P, Martino R, Murthy HS, Nishihori T, O'Brien TA, Olsson RF, Patel SS, Perales MA, Prestidge T, Qayed M, Romee R, Schoemans H, Seo S, Sharma A, Solh M, Strair R, Teshima T, Urbano-Ispizua A, Van der Poel M, Vij R, Wagner JL, William B, Wirk B, Yared JA, Spellman SR, Arora M, Hamilton BK. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide, Biol Blood Marrow Transplant, 2020 Aug;26(8):1459-1468.

Solomon SR, Solh M, Zhang X, Brown S, Jackson KC, Holland HK, Morris LE, Bashey A. Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant, Blood Adv., 2020 Aug 11;4(15):3669-3676.

Solh MM, Baron J, Zhang X, Bashey A, Morris LE, Holland HK, Solomon SR., Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors, Biol Blood Marrow Transplant, 2020 Aug 1: S10838791(20)30467-5.

Sutcliffe EG, Stettner AR, Miller SA, Solomon SR, Marshall ML, Roberts ME, Susswein LR, Arvai KJ, Klein RT, Murphy PD, Hruska KS., Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testing, Cancer Genet., 2020 Aug; 246-247:12-17.

Solomon SR, Martin AS, Zhang MJ, Ballen K, Bashey A, Battiwalla M, Baxter-Lowe LA, Brunstein C, Chhabra S, Perez MAD, Fuchs EJ, Ganguly S, Hardy N, Hematti P, McGuirk J, Peres E, Ringden O, Rizzieri D, Romee R, Solh M, Szwajcer D, van der Poel M, Waller E, William BM, Eapen M., Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant, Biol Blood Marrow Transplant. 2020 Jul 7.

Solh MM, Solomon SR, Morris LE, Zhang X, Holland HK, Bashey, Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine), A.Leuk Res., 2020 Jun;93:106318.

Farhadfar N, Murthy HS, Logan BR, Sees JA, Ayas M, Battiwalla M, Beitinjaneh AM, Chhabra S, Diaz MA, Engles K, Frangoul H, Ganguly S, Gergis U, Kamani NR, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Norkin M, O' Donnell PV, Olsson RF, Rossmann S, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Sugrue M, Yared JA, Linenberger M, Schwartz J, Pulsipher MA, Shah NN, Switzer GE, Confer DL, Shaw BE, Wingard JR. Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis, Bone Marrow Transplant, 2020 Jun 8.

Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, Maegawa RO, Savell A, Mazzeo M, Anderson A, Boardman AP, Weber A, Avigan D, Chen YB, Nikiforow S, Ho VT, Cutler C, Alyea EP, Bachireddy P, Wu CJ, Ritz J, Streicher H, Ball ED, Bashey A, Soiffer RJ, Armand P., A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation, Blood, 2020 Jun 11;135(24):2182

Roboz GJ, Larson ML, Rubenstein SE, Solomon SR, Schiller GJ, An Q, Chiarella M, Louie AC, Lin TL., Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia, Leuk Lymphoma, 2020 May;61 (5) :1188-1194.

Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall AT, Luber K, Masarova L, Michaelis LC, Patches S, Pariser AC, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos BR, Bacher U, Bashey A, Beitinjaneh AM, Cerny J, Chhabra S, Copelan E, Cutler CS, DeFilipp Z, Gadalla SM, Ganguly S, Grunwald MR, Hashmi SK, Kharfan-Dabaja MA, Kindwall-Keller T, Kröger N, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Nathan S, Nishihori T, Olsson RF, Pawarode A, Rowe JM, Savani BN, Savoie ML, Seo S, Solh M, Tamari R, Verdonck LF, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Mesa R, Saber W., Survival following allogeneic transplant in patients with myelofibrosis, Blood Adv., 2020 May 12

Farhadfar N, Hsu JW, Logan BR, Sees JA, Chitphakdithai P, Sugrue MW, Abdel-Azim H, Anderlini PN, Bredeson C, Chhabra S, Diaz MA, Ganguly S, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Lynch DK, Murthy HS, Olsson RF, Papari M, Przepiorka D, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Yared JA, Pulsipher MA, Shah NN, Switzer GE, Confer DL, Shaw BE, Wingard JR., Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield, Blood Adv., 2020 Feb 25;4(4):706-716.

Fatobene G, Rocha V, St Martin A, Hamadani M, Robinson S, Bashey A, Boumendil A, Brunstein C, Castagna L, Dominietto A, Finel H, Chalandon Y, Kenzey C, Kharfan-Dabaja M, Labussière-Wallet H, Moraleda JM, Pastano R, Perales MA, El Ayoubi HR, Ruggeri A, Sureda A, Volt F, Yakoub-Agha I, Zhang MJ, Gluckman E, Montoto S, Eapen M., Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR, J Clin Oncol., 2020 Feb 7:JCO1902408.

Dholaria B, Savani BN, Labopin M, Luznik L, Ruggeri A, Mielke S, Al Malki MM, Kongtim P, Fuchs E, Huang XJ, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, Ben Soussan P, Arnault Y, Handgretinger R, Roy DC, O'Donnell P, Bashey A, Solomon S, Romee R, Lewalle P, Gayoso J, Maschan M, Lazarus HM, Ballen K, Giebel S, Baron F, Ciceri F, Esteve J, Gorin NC, Spyridonidis A, Schmid C, Ciurea SO, Nagler A, Mohty M., Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT, Haematologica, 2020 Jan;105(1):47-58.

Solomon SR, Solh M, Jackson KC, Zhang X, K. Holland H, Bashey A, Morris LE., Real-world outcomes of unselected elderly acute myeloid leukemia patients referred to a leukemia/hematopoietic cell transplant program, Bone Marrow Transplant, 2020 Jan;55(1):189-198.

Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME., Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease, J Clin Oncol, 2019 Dec 20:JCO1903011.

Solomon SR, Solh M, Zhang X, Morris LE, Holland HK, Bashey A., Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy, Biol Blood Marrow Transplant, 2019 Nov;25(11):2211-2216.

Solomon SR, St Martin A, Shah NN, Fatobene G, Al Malki MM, Ballen KK, Bashey A, Bejanyan N, Bolaños Meade J, Brunstein CG, DeFilipp Z, Champlin RE, Fuchs EJ, Hamadani M, Hematti P, Kanakry CG, McGuirk JP, McNiece IK, Ciurea SO, Pasquini MC, Rocha V, Romee R, Patel SS, Vasu S, Waller EK, Wingard JR, Zhang MJ, Eapen M., Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy, Blood Adv., 2019 Oct 8;3(19):2836-2844.

LaPorte J, Leone K, Zhang X, Holland K, Morris L, Bashey A, Solh M, Solomon S, A unique schedule of palonosetron, ondansetron, and dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy, Journal of Oncology Pharmacy Practice, 2019 Sep;25(6):1336-1342.

Meybodi MA, Cao W, Luznik L, Bashey A, Zhang X, Romee R, Saber W, Hamadani M, Weisdorf DJ, Chu H, Rashidi A., HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis, Blood Adv., 2019 Sep 10;3(17):2581-2585.

Scott R. Solomon, Melhem Solh M, Katelin Jackson, Xu-Zhang, H. Kent Holland, Asad Bashey, Lawrence Morris, Real-world outcomes of unselected elderly acute myeloid leukemia patients referred to a leukemia/hematopoietic cell transplant program, Bone Marrow Transplant: accepted August 25, 2019

Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR., Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report, Clinical Cancer Research, 2019 Aug 15;25(16):5143-5155.

Solomon SR, Sizemore CA, Ridgeway M, Zhang X, Brown S, Holland H, Morris L, Solh M, Bashey A, Safety and efficacy of rituximab-based first line treatment of chronic GVHD, Bone Marrow Transplant, 2019 Aug;54(8):1218-1226.

Solomon SR, Solh M, Zhang X, Morris LE, Holland HK, Bashey A., Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy, Biology of Blood Marrow Transplant, 2019 Jun 25, S1083-8791(19)30381-7 10.1016.

Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh AM, Bejanyan N, Bhatt VR, Bolaños-Meade J, Byrne M, Cahn JY, Cairo M, Ciurea S, Copelan E, Cutler C, Daly A, Diaz MA, Farhadfar N, Gale RP, Ganguly S, Grunwald MR, Hahn T, Hashmi S, Hildebrandt GC, Holland HK, Hossain N, Kanakry CG, Kharfan-Dabaja MA, Khera N, Koc Y, Lazarus HM, Lee JW, Maertens J, Martino R, McGuirk J, Munker R, Murthy HS, Nakamura R, Nathan S, Nishihori T, Palmisiano N, Patel S, Pidala J, Olin R, Olsson RF, Oran B, Ringden O, Rizzieri D, Rowe J, Savoie ML, Schultz KR, Seo S, Shaffer BC, Singh A, Solh M, Stockerl-Goldstein K, Verdonck LF, Wagner J, Waller EK, De Lima M, Sandmaier BM, Litzow M, Weisdorf D, Romee R, Saber W., Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission, Blood Advances, 2019 Jun 25;3(12):1826-1836.

Karam E, Laporte J, Solomon SR, Morris LE, Zhang X, Holland HK, Bashey A, Solh M, Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?, Biology Blood Marrow Transplant, 2019 Jun 4. S1083-8791(19)30356-8.

Perales MA, Tomlinson B, Zhang MJ, St Martin A, Beitinjaneh A, Gibson J, Hogan W, Kekre N, Lazarus H, Marks D, McGuirk J, Romee R, Solh M, Wagner JE, Weisdorf DJ, de Lima M, Eapen M., Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical Donor?, Haematologica., 2019 May 17.

Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ., GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia, Blood Advances, 2019 May 14;3(9):1441-1449.

Saad A, Lamb L, Wang T, Hemmer MT, Spellman S, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Agrawal V, Aljurf M, Beitinjaneh AM, Bhatt VR, Buchbinder D, Byrne M, Cahn JY, Cairo M, Castillo P, Chhabra S, Diaz MA, Farhan S, Floisand Y, Frangoul HA, Gadalla SM, Gajewski J, Gale RP, Gandhi M, Gergis U, Hamilton BK, Hematti P, Hildebrandt GC, Kamble RT, Kanate AS, Khandelwal P, Lazaryn A, MacMillan M, Marks DI, Martino R, Mehta PA, Nishihori T, Olsson RF, Patel SS, Qayed M, Rangarajan HG, Reshef R, Ringden O, S. Impact of T Cell Dose on Ciurea SO, Cao K, Fernandez-Vina M, Kongtim P, Malki MA, Fuchs E, Luznik L, Huang XJ, Ciceri F, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, Handgretinger R, Roy DC, O'Donnell P, Bashey A, Lazarus HM, Ballen K, Savani BN, Mohty M, Nagler A., Correction: The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation, Bone Marrow Transplant, 2019 May;54(5):784.

Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P., Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma, Biology of Blood Marrow Transplant, 2019 Apr;25(4):683-688.

Solh M, Dickhaus E, Solomon SR, Morris LE, Zhang X, Holland HK, Bashey A., Fevers post infusion of T-cell replete HLA mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes, Bone Marrow Transplant, 2019 Apr 5.

Solh M, Solomon S, Morris L, Zhang X, Holland H, Bashey A, The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation, Biology of Blood Marrow Transplant, 2019 Mar;25(3):606-612.

Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J., Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203), Lancet Hematology, 2019 Mar;6(3):e132-e143.

Ciurea SO, Al Malki MM, Kongtim P, Fuchs EJ, Luznik L, Huang XJ, Ciceri F, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, Ben Soussan P, Arnault Y, Handgretinger R, Roy DC, O'Donnell PV, Bashey A, Solomon S, Romee R, Gayoso J, Lazarus HM, Ballen K, Savani BN, Mohty M, Nagler A., The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation, Bone Marrow Transplant, 2019 Mar 4.

Yeshurun M, Weisdorf D, Rowe JM, Tallman MS, Zhang MJ, Wang HL, Saber W, de Lima M, Sandmaier BM, Uy G, Kamble RT, Cairo MS, Cooper BW, Cahn JY, Ganguly S, Camitta B, Verdonck LF, Dandoy C, Diaz MA, Savani BN, George B, Liesveld J, McGuirk J, Byrne M, Grunwald MR, Drobyski WR, Pulsipher MA, Abdel-Azim H, Prestidge T, Wieduwilt MJ, Martino R, Norkin M, Beitinjaneh A, Seo S, Nishihori T, Wirk B, Frangoul H, Bashey A, Mori S, Marks DI, Bachanova V, The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia, Blood Advances, 2019 Feb 26;3(4):670-680.

Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A, Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial, Journal of Clinical Oncology, 2019 Mar 1;37(7):589-597.

Mchayleh W, Bedi P, Sehgal R, Solh M., Chimeric Antigen Receptor T-Cells: The Future is Now, Journal of Clinical Medicine, 2019 Feb 7;8 (2).

Norkin M, Shaw BE, Brazauskas R, Tecca HR, Leather HL, Gea-Banacloche J, T Kamble R, DeFilipp Z, Jacobsohn DA, Ringden O, Inamoto Y, A Kasow K, Buchbinder D, Shaw P, Hematti P, Schears R, Badawy SM, Lazarus HM, Bhatt N, Horn B, Chhabra S, M Page K, Hamilton B, Hildebrandt GC, Yared JA, Agrawal V, M Beitinjaneh A, Majhail N, Kindwall-Keller T, Olsson RF, Schoemans H, Gale RP, Ganguly S, A Ahmed I, Schouten HC, L Liesveld J, Khera N, Steinberg A, Shah AJ, Solh M, Marks DI, Rybka W, Aljurf M, Dietz AC, Gergis U, George B, Seo S, Flowers MED, Battiwalla M, Savani BN, Riches ML, Wingard JR., Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation, Biology Blood Marrow Transplant, 2019 Feb;25(2):362-368.

Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh M, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK, Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation, Biology of Blood Marrow Transplant, 2019 Jan;25(1):73-85.

Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A., Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups, Biology of Blood Marrow Transplant, 2018 Dec;24(12):2443-2449.

Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W., Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia, Blood Advances, 2018 Nov 13;2(21):2922-2936.

Spellecy R, Tarima S, Denzen E, Moore H, Abhyankar S, Dawson P, Foley A, Gersten I, Horwitz M, Idossa L, Joffe S, Kamani N, King R, Lazaryan A, Morris L, Horowitz MM, Majhail NS, Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study, Biology of Blood Marrow Transplant, 2018 Oct;24(10):2145-2151.

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE., Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML), Leukemia Research, 2018 Sep;72:92-95.

Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC., CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia, Journal of Clinical Oncology, 2018 Sep 10;36(26):2684-2692.

Bashey ZA, Zhang X, Brown S, Jackson K, Morris LE, Holland HK, Bashey A, Solomon S, Solh M., Comparison of outcomes following transplantation with T-replete HLA-haploidentical donor using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older, Bone Marrow Transplant, 2018. June; 53 (6):756-763.

Solomon S, Zhang X, Holland HK, Morris LE, Solh M, Bashey A., Superior survival of black versus white patients following post-transplant cyclophosphamide-based haploidentical= transplantation for adults with hematologic malignancy, Biology of Blood & Marrow Transplantation, 2018. June;24(6):1237-1242.

Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A, Bolaños-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S, Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN, Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, Hamadani M, Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure, Cancer, 2018 Jun 15;124(12):2541-2551.

Robinson TM, Fuchs EJ, Zhang MJ, St Martin A, Labopin M, Keesler DA, Blaise D, Bashey A, Bourhis JH, Ciceri F, Ciurea SO, Devine SM, Mohty M, McCurdy SR, Milpied N, McNiece IK, Rocha V, Romee R, Socie G, Yakoub-Agha I, Soiffer RJ, Eapen M, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant and the Center for International Blood and Marrow Transplant Research, Related donor transplants: has post transplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?, Blood Advances, 2018 Jun 12;2(11):1180-1186.

Medeiros BC, Tanaka TN, Balaian L, Bashey A, Guzdar A, Li H, Messer K, Ball ED., A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia, Clinical Lymphoma Myeloma Leukemia, 2018 May;18(5):346-352.e5.

Ciurea S, Cao K, Fernadez-Vina M, Kongtim P, Malki M, Fuchs E, Luznik L, Huang X, Ciceri F, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, Handgretinger R, Roy D, O'Donnell P, Bashey A, Lazarus H, Ballen K, Savani B, Mohty M, Nagler A., The European Society for Blood and Marrow Transplantation (EBMT)consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation, Bone Marrow Transplant, 2018 May;53(5):521-534.

Solh M, Bashey A, Solomon S, Morris LE, Zhang X, Brown S, Holland HK, Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients, Bone Marrow Transplant, 2018. May; 53(5):576-586.

Kumar AJ, Kim S, Hemmer MT, Arora M, Spellman SR, Pidala JA, Couriel DR, Alousi AM, Aljurf MD, Cahn JY, Cairo MS, Cutler CS, Farhan S, Gergis U, Hale GA, Hashmi SK, Inamoto Y, Kamble RT, Kharfan-Dabaja MA, MacMillan ML, Marks DI, Nakasone H, Norkin M, Qayed M, Ringden O, Schouten HC, Schultz KR, Solh MM, Teshima T, Urbano-Ispizua A, Verdonck LF, Gale RP, Hamilton BK, Majhail NS, Loren AW., Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants, Blood Advances, 2018 May 8;2(9):1022-1031.

Solomon S, Aubrey MT, Zhang X, Piluso A, Freed BM, Brown S, Jackson K, Morris LE, Holland HK, Solh M. Bashey A., Selecting the best donors for haploidentical transplant: Impact of HLA killer cell immunoglobulin-like receptors genotyping, and other clinical variables, Biology of Blood & Marrow Transplantation, 2018. Apr;24(4):789-798.

McCurdy SR, Zhang MJ, St Martin A, Al Malki MM, Bashey A, Gaballa S, Keesler DA, Hamadani M, Norkin M, Perales MA, Reshef R, Rocha V, Romee R, Solh M, Urbano-Ispizua A, Waller EK, Fuchs EJ, Eapen M., Effect of donor characteristics on haploidentical transplantation with post transplantation cyclophosphamide, Blood Advances, 2018 Feb 13;2(3):299-307.

Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, Choi SW, DeFilipp Z, Gadalla SM, Gale RP, Gergis U, Hashmi S, Hematti P, Holmberg L, Inamoto Y, Kamble RT, Lehmann L, MacMillan MA, McIver Z, Nishihori T, Norkin M, O'Brien T, Olsson RF, Reshef R, Saad A, Savani BN, Schouten HC, Seo S, Solh M, Verdonck L, Vij R, Wirk B, Yared J, Horowitz MM, Knight JM, Verneris MR., Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation, Bone Marrow Transplant, 2018 Jan 30.

Solh M. Zhang X, Connor K, Brown S, Morris LE, Holland HK, Bashey A, Solomon SR., Donor type and disease risk predict the success of allogeneic hematopoietic cell transplantation: A single center analysis of 613 adult hematopoietic cell transplantation recipients using a modified endpoint, Biology of Blood & Marrow Transplantation, 2017. Dec;23(12):2192-2198.

Bashey A, Zhang M, Mccurdy S St. Martin A, Argall T, Ciurea S, Fasan O, Gaballa S, Hamadani M, Munshi P, Al Malki M, Nakamura R, O’Donnell P, Pereles M, Raj K, Romee R, Rowley S, Rocha V, Salit R, Solh M, Soiffer R, Fuchs E, Eapen M., Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell replete haploidentical donor using post- transplant cyclophosphamide, Journal of Clinical Oncology, 2017 Sep10;35(26):3002-9.

Holstein S, Jung S, Richardson P, Hofmeister C, Hurd D. Hassoun H, Giralt S, Stadtmauer E, Weisdorf D, Vij R. Moreb J. Callander N, Van Besein K, Gentile T, Isola L, Maziarz R. Bashey A. Landau H, Martin T, Qazilbash M, Rodriguez C, McClune B, Schlossman R, Smith S, Hars V, Owzar K, Boyd M, Schultz C, Wilson M, Hari P, Pasquini M, Horowitz M, Shea T, Devine S, Linker C, Anderson K, McCarthy P. , Updated analysis of CALGB (alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem cell transplantation for multiple myeloma: a randomized, double blind phase 3 trial, Lancet Hematology, 2017. Sept;4 (9).

Webster J, Tibes R, Morris LE, et.al., Randomized Phase II Trial of Cytosine Arabinoside With and Without the CHK1 Inhibitor MK-8776 in Relapse and Refractory Acute Myeloid Leukemia, Leukemia Research, 2017, Sept. In Press.

Solh M. Zhang X, Connor K, Brown S, Morris LE, Holland HK, Bashey A, Solomon SR., Donor type and disease risk predict the success of allogeneic hematopoietic cell transplantation: A single center analysis of 613 adult hematopoietic cell transplantation recipients using a modified endpoint, Biology of Blood & Marrow Transplantation, 2017, Aug 30.

Solomon S, Sizemore C, Zhang X, Ridgeway M, Solh M, Morris LE, Holland HK, Bashey A. Current Graft-versus host disease free. Relapse-free survival: A dynamic endpoint to better define efficacy after allogenic transplant, Biology of Blood & Marrow Transplantation, 2017, Jul;23(7):1208-1214.

Hamilton B, Rybicki L, Abounader D, Adekola K, Aldoss I, Bachanova V, Bashey A, Brown S, DeLima M, Devine S, Flowers C, Ganguly S, Jagasia M, Kennedy V, Kim D, McGuirk J, Pullarkat V, Romee R, Sandhu K, Smith M, Ueda M, Viswabandya A, Vu K, Wall S, Zeichner S, Perales M, Majhail N, Advani A., Allogeneic hematopoietic cell Transplantation for adult T cell acute lymphoblastic leukemia, Biology of Blood & Marrow Transplantation, 2017. Jul;23(7):1117-1121.

Haverkos B, Abbott D, Hamandani M, Armand P, Flowers M, Merryman R, Kamdar M Kanate A, Saad A, Mehta A, Ganguly S, Fenske T, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bashanova V, Stephens d, Mineishi S, Nakamura R, Chen Y, Blazar B, Gutman J, Devine S., PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high rate but frequent GVHD, Blood, 2017. July13;130(2):221-228.

Gerds A, Woo a, Hu Z, Abdel Azim H, Akpek G Aljurf M, Ballen K, Beitinjaneh A, Bacher U, Cahn J, Chhabra S, Cutler C, Daly A, Deflipp Z, Gale R, Gergis U Grunwald M, Hale G, Hamilton B, Jagasia M, Kamble R, Kindwall-Keller T, Nishihori T, Olsson R, Ramanathan M, Saad A, Solh M. Ustun C, Valcarcel D, Warlick E, Wirk B, Kalaycio M, Alyea E, Popat U, Sobecks R, Saberr W., Outcomes after umbilical cord blood transplantation for myelodysplastic syndrome, Biology of Blood & Marrow Transplantation, 2017 June;23(6):971-79.

Khoury H, Wang T, Hemmer M, Couriel D, Alousi A, Cutler C, Aljurf M, Antin J, Ayas M, Battiwalla M, Cahn J, Cairo M, Chen Y, Gale R, Hashmi S, Hayashi R, Jagasia M, Juckett M, Kamble R, Kharfan-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoeman H, Schouten H, Socie G, Storek J, Verdonck L, Vij R, Wood WA Yu L, Martino R, Carabasi M, Dandoy C, Gergis U. Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz K, Wirk B, Spellman S, Arora M, Pidala J. , Improved survival after acute graft-versus-host disease diagnosis in modern era, Haematologica, 2017 May;102(5): 958-66.

Brunstein C, Zhang M, Baker J, St. Martin A, Bashey A, DeLima M, Dehn J, Hematti P, Perales M, Rocha V, Territo M, Weisdorf D, Eapen M., The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia, Haematologica, 2017. May;102(5):941-947.

Scott B, Pasquini M, Logan B, Wu J, Devine S, Porter D, Maziarz R, Warlick E, Fernandez H, Alyea E, Hamadani M, Bashey A, Giralt S, Geller N, Leifer E, Le-Rademacher J, Mendizabal A, Horowitz M, Deeg H, Horwitz M., Myeloablative versus reduced intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes, Journal of Clinical Oncology, 2017, Apr10;35(11): 1154-1161.

Cornell R, D’Souza A, Kassim A, Costa L, Innis-Shelton R, Zhang M, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz M, Freytes C, Gale R, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble R, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Lazarus H, Lee C, aiolino A, Marks D, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson R, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk B, Yared J, Krishnan A, Mark T, Nieto Y, Hari P., Maintenance versus induction therapy choice on outcomes after autologous transplantation for multiple myeloma, Biology of Blood & Marrow Transplantation, 2016, 11. 011 Nov 14.

Srour S, Milton D, Bashey A, Karduss-Urueta A, Malki M, Romee R, Solomon S, Brown S, Slade M, Perez R, Rondon G, Forman S, Champlin R, Kabriaei P, Ciurea S., Haploidentical transplantation with post-transplantation cyclophosphamide for high risk acute lymphoblastic leukemia, Biology of Blood & Marrow Transplantation, 2016, Oct; 22(10): 1861-1866.

Solomon SR, Sizemore C, Zhang X, Brown S, Holland HK, Morris LE, Solh M, Bashey A, Donor type and disease risk predict the success of allogeneic hematopoietic cell transplantation for acute leukemia, Biology of Blood and Marrow Transplantation, October, 2016, Vol. 22, Issue 10, pages 1816–1822.

Solh M, Solomon S, Morris L, Holland HK, Bashey A., Extramedullary Acute Myelogenous Leukemia, Blood, Sept; 30(5):333-9.

Alvarnas JC, Le Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine S, Baiocchi R, Lozanski G, Kaplan L, Noy A, Popat U, Hsu J, Morris LE, Thompson J, Horowitz MH, Mendizabal A, Levine A, Krishnan A, Forman SJ, Navarro WH, Ambinder RF. , Autologous hematopoietic cell transplantation for HIV-related lymphoma: Results of the BMT CTN 0803 (AMC) 071 Trial, Blood, 2016. Aug 25; 128(8):1050-8.

Gorgeis J, Zhang X, Connor K, Brown S, Solomon SR, Morris LE, Holland HK, Bashey A, Solh M., T-Cell replete HLA-haploidentical donor transplantation (HIDT) with post-transplant cyclophosphamide (PTCY) is an effective salvage for patients relapsing after an HLA-matched related (MRDT) or a matched unrelated donor transplantation (MUDT), Biology of Blood & Marrow Transplantation, 2016 Oct;22(10): 1861-6

Solomon SR., Haploidentical versus matched unrelated donor PBSC transplant AML: Should donor type matter anymore?, Biology of Blood & Marrow Transplantation, 2016 Sept; 22(9):1540-2.

Solh M, Zhang X, Connor K, Brown S, Solomon SR, Morris LE, Holland HK, Bashey A., Factors predicting graft-versus-host disease-free. Relapse-free survival after allogeneic hematopoietic cell transplantation: Multivariable analysis from a single center, Biology of Blood & Marrow Transplantation, 2016, Aug;22(8):1403-1409.

Solh M, Zhang X, Connor K, Brown S, Solomon SR, Morris LE, Holland HK, Bashey A., Post-relapse survival after haploidentical transplantation vs matched-related or matched unrelated hematopoietic cell transplantation, Bone Marrow Transplantation, 2016 Jul;51(7):949-54.

Davids M. Kim H, Bachireddy P, Costello C, Liguori R, Savell A, Lukez A, Avigan D, Chen Y, McSweeney P, LeBoeuf N, Rooney M, Bowden M, Zhou C, Granter S, Hornick J, Rodig S, Hirakawa M, Severgnini M, Hodi F, Wu C, Ho V, Cutler C, Koreth J, Alyea E, Antin J, Armand P, Streicher H, Ball E, Ritz J, Bashey A, Soiffer R., Ipilimumab for patients with relapse after allogeneic transplantation. Leukemia and Lymphoma Society Blood Cancer Research Partnership, New England Journal of Medicine, 2016, July 14;375(2): 143-53.

Oyer JL, Pandey V, Igarashi RY, Somanchi SS, Zakari A, Solh M, Lee DA, Altomare DA, Copik AJ., NK cells stimulated with PM21 particles expand and biodistribute in vivo: clinical implications for cancer treatment, Cryotherapy, 2016 May;18(5):653-63.

Solh M, Shanley R, Mc Cullough J, Weisdorf D., Blood transfusions and pulmonary complications following hematopoietic cell transplantation, Transfusion, 2016 Mar;56(3):653-61.

Solomon, SR, Haploidentical versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia: Should Donor Type Matter Anymore?, Biology of Blood and Transplantation, Volume 22, Issue 1, January 2016, Pages 125-133.

Solomon SR, Solh M, Morris LE, Holland HK, Bashey A., Myeloablative conditioning with PBSC grafts for T Cell-Replete haploidentical donor transplantation using post-transplant cyclophosphamide, Hindawi Publishing Corporation: Advances in Hematology, Vol. 2016 Article ID 9736564 7 pages.

Bashey A, Zhang X, Jackson K, Brown S, Ridgeway M, Solh M, Morris LE, Holland HK, Solomon SR, Comparison of Outcomes of Hematopoietic Cell Transplant from T-Replete Haploidentical Donors Using Post Transplant Cyclophosphamide with 10 of 10 HLA-A, -B,-C, -DRB1, and –DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis including Disease Risk Index, Biology of Blood and Transplantation, Volume 22, Issue 1, January 2016, Pages 125-133.

LaPorte J, Solh M, Ouanounou S., Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed hodgkin’s lymphoma, Journal of Clinical Practice, 2015 Dec 11.

Klyuchnikov E, Bacher U, Kroger NM, Hari Pn, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D’Souza A, Freytes CO, Gale RP, Ganguly S Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Millier AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M., Reduced-intensity allografting as first transplantation approach in relapse/refractory grade one and two follicular lymphoma provides improved outcomes in long-term survivors, Biology Of Blood and Marrow Transplantation, 2015 Dec; 21 (12): 2091-2099.

Inamoto Y, Flowers ME, Wang T, Solh M, et al. Tacrolimus versus cyclosporine after hematopoietic cell transplantation for acquired aplastic anemia, Biology Of Blood and Marrow Transplantation, 2015 Oct; 21(10):1776-82.

Seftel M, Neuberg D, Zhang M, Wang H, Akpek G, Bachanova V, Bacher U, Ballen K, Baron F, Bashey A, Bergeron J, Cahn J, Camitta B, Copelan E, Couban S, DeAngelo D, Lima M, Deol A, Freytes C, Gale R, Gergis U, Hamadani M, Hogan W, Kebriaei P Kharfan-abaja M, Lazarus H, Litzow M, Loren A, Miller A, Nishihori T, Norkin M, Olsson RR., Reshef R, Saber W, Sabloff M, Sandmaier B, Sallan S, Savani B, Schouten H, Tallman M, Vij R, Woolfrey A, Wiernik P, Wirk B, Wood W, Weisdorf D., Superior outcomes of Pediatric-inspired intensive chemotherapy over allogeneic hematopoietic cell Transplantation for Philadelphia chromosome negative adult all in first complete Remission: A combined analysis of Dana-Farber All Consortium and CIBMTR Cohorts, The Lancet Oncology, 2015.

Solomon SR, Sizemore CA, Ridgeway M, Zhang X, Smith J, Brown S, Holland HK, Morris LE, Bashey A., Costicosteroid-free primary treatment of chronic extensive graft-versus-host disease incorporating rituximab, Biology of Blood & Marrow Transplantation, 2015 Sept;21(9): 1576-1582.

Zeidner J, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE., Radomized multi-center phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (flam) versus cytarabine/ daunorubicin (7+3) in newly diagnosed acute myeloid leukemia, Haematologica, 2015 Sept; 100(9):1172-9.

Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS,Armand P, Antin JH, Chen J, Devine SM, Fowler DH, Luznik L, Nakamura R, O’Donnell PV, Perales MA, Pingali SR, Porter DL, Riches MR, Ringden OT, Rocha V, Vij R, Weisdorf DJ, Champlin RE, Horowitz MM, Fuch EJ, Eapen M., Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia, Blood, 2015 Aug 20; 126(8): 1033-1040.

Solomon SR, Sizemore C, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A., Total Body Irradiation-based myeloablative haploididentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors, Biology of Blood & Marrow Transplantation, 2015 July;21(7):1299-1307.

Solh T, Botsford A, Solh M., Glanzmann’s thrombasthenia: pathogenesis, diagnosis and current and emerging treatment options, J Blood Med, 2015 July 8; 6:219-27

Holland KH., New Targeted Treatments for Hematological Malignancies, Atlanta Medicine: Journal of the Medical Association of Atlanta, 2015, July Vol.86, No. 2:12-17.

Sanacore M, Zhang X, Brown S, Connor K, Hilton S, Morris LE, Holland HK, Solomon SR, Bashey A., Referential depletion of host over donor T-cells through in vivo decay of active rabitt-anti-thymocyte globulin levels during reduced intensity conditioning, Bone Marrow Transplantation, 2015 Jun;50(6): 829-833.

LaPorte J, Morris LE, Koepke J., Long complete remission achieved with the combination therapy of cisplatin and gemcitabine in patients with aggressive natural killer cell leukemia, Case Reports in Hematology, Volume 2015, Article ID 715615.

Leech M, Morris L, Stewart M, Smith BD, Bashey A, Holland K, Solomon S, Zhang X, Carraway HE, Pratz K, Gore SD, Zeidan AM., Real-life experience of a brief arsenic toxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: Favorable outcomes with limited anthracycline exposure and shorter consolidation therapy, Clinical Lymphoma, Myeloma, Leukemia, 2015 May;15(5): 292-297.

Oyer JL, Igarashi R, Solh M, Copik AJ., Generation of highly cytotoxic natural killer cells for treatment of AML using a feeder free, particle-based approach, BBMT, 2015 April; 21(4):632-9.

Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B., Phase III open-lable randomized study of cytarabine incombination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia, Journal of Clinical Oncology 2015 Apr 10;33(11): 1252-1257.

Batista A, Lamontagne D, Solh M., Processing the 5-ml umbilical cord blood unit with the use of an automated wash procedure, Cytotherapy 2015 Mar;17(3):336-7.

Arai S, Arora M, Solh M, Pavletic SZ., Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research, BBMT, 2015 Feb;21(2):266-74.

Freytes CO, Toro JJ, Yeh RF, Stadtmauer EA, Ratanatharathorn V, Akpek G, Sahovic E, Tricot GJ, Shaughnessy PJ, White DJ, Rodriguez TE, Solomon SR, Yu LH, Zhao C, Patil S, Armstrong E, Smith A, Elekes A, Kato K, Reece DE., Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation, Biology of Blood and Marrow Transplantation, 2014; Dec;20(12): 1949-57.

Bashey A, Solomon SR., T-Cell replete haploidentical donor transplantation using post transplant CY”: An emerging standard of care option for patients who lack and HLA-identical sibling donor, Bone Marrow Transplantation, 2014, Aug;49(8): 999-1008.

Bashey, A, Solomon, S., T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor, Bone Marrow Transplantation, advance online publication, 19 May 2014; doi:10.1038/bmt.2014.62.

Roboz GJ, Rosenblat T, Arellano M, Gobbi M, Altman JK, Montesinos P, O’Connell C, Solomon, SR, Pigneax A, Vey N, Hills R, Jacobsen TF, Gianella Boradori A, Foss O, Vetrhusand S, Giles FJ., International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed refractory acute myeloid leukemia, Journal of Clinical Oncology, 2014; 32(18):1919-1926.

Sabloff M, Sobecks RM, Ahn KW, Zhu X, De Lima M, Brown JR, Inamato Y, Holland HK, Aijurf MD, Laughlin MJ, Kamble RT, Hsu JW, Wirk BM, Seftel M, Lewis ID, Arora M, Alyea EP, Kalaycio ME, Cortis J, Maziarz RT, Gale RP, Saber W., Does total body irradiation conditioning improve outcoes of myeloablative human leukocyte antigen identical sibling transplantations for chronic phocytic leukemia?, Biology of Blood & Marrow Transplantation, 2014 Mar; 20(3) 421-424.

Solomon SR, SanacoreM, Zhang X, Brown, S, Holland K, Morris, LE, Bashey A., Calcineurin Inhibitor (DNI)-Free GVHD Prophylaxis with Post-Transplant Cyclophosphamide (CY) and Brief-Course Sirolimus Following Reduced Intensity Peripheral Blood Stem Cell Transplantation, Biology of Blood and Marrow Transplantation (2014), doi: 10,1016/j.bbmt.2014.07.020.

Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ., Phase 2 trial of CPX 351, a fixed 5:1 molar ratio of cytarabine/daunorubicin vs cytarabine/daunorubicin in older adults with untreated AML, Blood, 2014;123(21):3239-3246.

Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobaldi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA,Landau H, Schouten HC, Maziarz RT, Michael J, Kindwall-Keller T, Stiff PJ, Gibson J,Lonial S, Krishnan A, Dispenzieri A, Hari P. , Salvage second hematopoietic cell transplantation cell transplantation in myeloma. Plazma Cell Disorders Working Committee of The Blood and Marrow Transplant, Biology of Blood & Marrow Transplantation, 2013 May; 19(5): 760-6.

Bashey A., Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, Morris LE, and Solomon SR., T-Cell Replete HLA-Haploidentical Hematopoietic Transplants For Hematologic Malignancies Using Post-Transplant Cyclophosphamide Result In Equivalent Outcomes To Contemporaneous Transplants From HLA-Identical and Matched Unrelated Donors, Journal of Clinical Oncology 2013; Apr;31(10):310-1316.

Solomon S, Sizemore C, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A., Haploididentical Transplantation Using T-Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of a Prospective Phase II Trial, Biology of Blood & Marrow Transplantation, 2012 December; 18(12): 1859-1866.

Philip L. McCarthy, M.D., Kouros Owzar, Ph.D., Craig C. Hofmeister, M.D., David D. Hurd, M.D., Hani Hassoun, M.D., Paul G. Richardson, M.D., Sergio Giralt, M.D., Edward A. Stadtmauer, M.D., Daniel J. Weisdorf, M.D., Ravi Vij, M.D., Jan S. Moreb, M.D., Natalie Scott Callander, M.D., Koen Van Besien, M.D., Teresa Gentile, M.D., Ph.D., Luis Isola, M.D., Richard T. Maziarz, M.D., Don A. Gabriel, M.D., Ph.D., Asad Bashey, M.D., Ph.D., Heather Landau, M.D., Thomas Martin, M.D., Muzaffar H. Qazilbash, M.D., Denise Levitan, M.D., Brian McClune, M.D., Robert Schlossman, M.D., Vera Hars, M.S., John Postiglione, B.A., Chen Jiang, Ph.D., Elizabeth Bennett, B.H.E., Susan Barry, B.A., Linda Bressler, Pharm.D., Michael Kelly, M.A., Michele Seiler, M.S., Cara Rosenbaum, M.D., Parameswaran Hari, M.D., Marcelo C. Pasquini, M.D., Mary M. Horowitz, M.D., Thomas C. Shea, M.D., Steven M. Devine, M.D., Kenneth C. Anderson, M.D., and Charles Linker, M.D., Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma, New England Journal of Medicine, 2012; 366:1770-1781 May 10, 2012.

Vogl D, Wang T, Perez W, Stadtmauer E, Heitjan D, Lazarus H, Kyle, RA, Kamble R, Weisdorf D, Roy V, Ballen K, Holmberg L, Bashey A, McCarthy P, Freytes C, Maharaj D, Maiolino A, Vesole D, Hari P., Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma, Biology of Blood & Marrow Transplantation, 2011 Dec;17(12): 1765-74.

Judith E. Karp, Tatiana I.Vener, Mitch Raponi, Ellen K. Ritchie, B.Douglas Smith, Steven D. Gore, Lawrence E. Morris, Eric J. Feldman, acqueline M.Greer, Sami Malek, Hetty E. Carraway, Valerie Ironside, Steven Galkin, Mark J.Levis, Michael A. McDevitt, Gail R. Roboz, Christopher D. Gocke, Carlo Derecho, John Palma, Yixin Wang, Scott H. Kaufman, John J. Wright and Elizabeth Garrett-Mayer, Multi-institutional Phase II clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia, Blood, 2011 October 14.

Bashey A, Owzar K, Johnson JL, Edwards PS, Kelly M, Baxter-Lowe LA, Devine S, Farag S, Hurd D, Ball E, McCarthy P, Lister J, Shea TC, Linker C. , Reduced – Intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: A multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002), Biology of Blood & Marrow Transplantation, 2011 Apr;17(4) 558-65.

Shea T, Johnson J, Westervelt P, Farag S, McCarty J, Bashey A, Isola L, Baxter-Lowe LA, Kelly M, Owzar K, Linker C; For the Cancer leukemia Group B. Reduced-intensity Allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901, Biology of Blood & Marrow Transplantation, 2011 Feb 3.

Chu R, Bazauskas R, Kan F, Bashey A, Bredeson C, Camitta B, Chiang KY, Frangoul H, Gale RP, Gee A, George B, Goldman FD, Gross TG, Gupta V, Hale GA, Isola L, Ispizua AU, Lazarus H, Marsh J, Russell J, Sabloff M, Waller EK, Eapen M., Comparison of outcomes after transplantation of G-CSF – stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia, Biology of Blood & Marrow Transplantation, 2010 October 27.

Zhou J, Bashey A, Zhong R, Corringham S, Messer K, Pu M, Ma W, Soiffer R, Mitrovich RC, Lowy I, Ball ED., CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not increased levels of T regulatory cells, Biology of Blood & Marrow Transplantation, 2010 Aug 13.

Kasamon Y, Luznik L, Leffell M, Kowalski J, Tsai H, Bolanos-Meade J, Morris LE, Crilley P, O’donnell P, Rossiter N, Huff C, Brodsky R., Nonmyeloablative HLA-haploidentical BMT with high dose post transplantation cyclophosphamide: analysis of outcomes in relation to HLA disparity, Biology of Blood and Marrow Transplantation, 2010 April;16(4): 482-9.

Solomon SR, Matthews RH, Barreras AM, Bashey A, Manion KL, McNatt K, Speckhart D. Connaghan DG, Morris LE, Holland HK., Outpatient myeloablative allo-SCT: a comprehensive approach yields decrease hospital utilization and low TRM, Bone Marrow Transplantation, 2010 March;45(3): 468-75.

Ballen K, Shrestha S, Sobocinski K, Zhang M, Bashey A, Bolwell B, Cervantes F, Devine S, Gale R, Gupta V, Hahn T, Hogan W, Kroger N, Litzow M, Marks D, Maziarz R, McCarthy P, Schiller G, Schouten H, Wiernik P, Horowitz M, Giralt S, Arora M., Outcome of Transplantation for Myelofibrosis, Biology of Blood & Marrow Transplantation, 2010 March; 16(3): 358-67.

Hari P, Majhail N, Zhang M, Hassebroek A, Siddiqui F, Ballen K. Bashey A, Bird J, Freytes C, Gibson J, Hale G, Holmberg L, Kamble R, Kyle R, Lazarus P, LeMaistre C, Loberiza F, Maiolino A, McCarthy P, Milone G, Omondi N, Reece D, Seftel M, Trigg M, Vesole D, Weiss B, Wiernik P, Lee S, Rizzo J, Mehta P., Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma, Biology of Blood & Marrow Transplantation, 2010 March;16(3): 395-402.

Gore S, Gojo I, Sekeres M, Morris LE, et al., A Single Cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia, Journal of Clinical Oncology, 2010 Feb 20; 28(6): 1047-53.

Schiller GL, O'Brien SM, Pigneux A, DeAngelo DJ, Vey N, Kell J, Solomon S, Stuart RK, Karsten V, Cahill AL, Albitar MX, Giles FJ. Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia, J Clin Onc, 2010; 28(5):815-821.

Reese DE, Vesole DH, Shrestha S, Zhang MJ, Perez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredeson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, Kumar S, Kyle RA, Lazarus HM, McCarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wiernik PH, Hari PN, Outcome of patients with IgD and IgM Multiple Myeloma undergoing Autologous hematopoietic stem cell transplantation: A retrospective CIBMTR Study, Clinical Lymphoma Myeloma Leukemia, 2010 Dec1;10(6): 458-63.

Jung A, Holman P, Castro J, Carrier E, Bashey A, Lane T, Nelson C, Pu M, Messer K, Corringham S, Ball E., Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia, Biology of Blood & Marrow Transplantation, 2009 Oct;15(10): 1306-13.

Hari P, Zhang M, Roy V, Perez W, Bashey A, To LB, Elfenbein G, Freytes C, Gale R, Gibson J, Kyle R, Lazarus H, McCarthy P, Milone G, Pavlovsky S, Reece D, Schiller G, Vela-Ojeda J, Weisdorf D, Vesole D., Is the international staging system superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant, Leukemia, 2009 August;23(8): 1528-34.

Karp J, Flatten K, Feldman E, Greer J, Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith DB, IronsideV, Talbott T, Roboz G, Le SB, Meng XW, Schneider PA, Dai NT, Adjei AA, Gore S, Levis MJ, Wright JJ, Garrett- Mayer E, Kaufmann S.H., Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: A preclinical and phase I trial of the farnesyltransferase inhibitor tripifarnib (R115777, Zarnestra) combined with etoposide, Blood, 2009 May 14;113(20): 4841-52.

Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, Solomon SR, Morris LE, Holland HK, Mason JR, Alyea EP, Soiffer RJ, Ball ED., CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation, Blood, 2009 Feb 12; 113(7): 1581-8.

Kumar S, Perez WS, Zhang MJ, Ballen K, Bashey A, To LB, Bredeson CN, Cairo MS, Elfenbein GJ, Freytes CO, Gale RP, Gibson J, Kyle RA, Lacy MQ, Lazarus HM, McCarthy PL, Milone GA, Moreb JS, Pavlovsky S, Reese DE, Vesole DH, Wiernik PH, Hari P., Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation, Biology of Blood & Marrow Transplantation, 2008 Oct;14;(10): 1134-40.

Bashey A, Perez WS, Zhang MJ, Anderson KC, Ballen K, Berenson JR, To LB, Fonseca R, Freytes CO, Gale RP, Gibson J, Giralt SA, Kyle RA, Lazarus HM, Maharaj D, McCarthy PL, Milone GA, Nimer S, Pavlovsky S, Reece DE, Schiller G, Vesole DH, Hari P, Plasma Cell Disorders Working Committee. Comparison of Twin and autologous transplants for multiple myeloma, Biology of Blood & Marrow Transplantation, 2008 Oct; 14(10): 1118-24.

Smith SM, Van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO, Gale RP, Hale GA, Hayes-Lattin B, Holmberg LA, Keating A, Maziarz RT, McCarthy PL, Navarro WH, Paviovsky S, Schouten HC, Seftel M, Wiernik PH, Vose JM, Lazarus HM, Hari P., Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant, Biology of Blood & Marrow Transplantation, 2008 Aug;14(8):904-12.

Karp JE, Smith BD, Gojo I, Lancet JE, Greer J, Klein M, Morris LE, Levis MJ, Gore SD, Wright JJ, Garrett-Mayer E., Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor risk features, Clinical Cancer Research, 2008 May; 14(10): 3077-82.

Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M, Carella A, Blaise D, Bashey A, Bitran JD, Bolwell BJ, Elfenbein GJ, Fields KK, Freytes CO, Gale RP, Lazarus HM, Champlin RE, Stiff PJ, Niederwieser D., Allogeneic. Hematopoietic cell transplantation for metastatic breast cancer, Bone Marrow Transplant, 2008, Mar;41(6): 537-45.

Raponi M, Lancet J, Hongtao F, Dossey L, Lee G, Gojo I, Feldman E, Gotlib J, Morris LE, Greenberg P, Wright J, Harousseau J, Lowenberg B, Stone R, De Porre P, Wang Y, Karp J., A two-gene classifier for predicting response to the farnesyltransferase Ihibitor tipifarnib in acute myeloid leukemia, Blood, 2008 Mar 1; 111(5): 2589-96.

Schlenk RF, Pasquini MC, Perez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Buchner T, Cahn JY, Cairo MS, Copelan EA, Cutler CS, Dohner H, Gale RP, Ilhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, Horowitz MM, Ganser A; CIBMTR Acute Leukemia Working Committee. HLA-Identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: Collaborative study between the German AML Intergroup and CIBMTR, Biology of Blood & Marrow Transplantation, 2008 Feb; 14(2):187-96.

Karp JE, Giles FJ, Gojo I, Morris LE, Greer J, Johnson B, Thein M, Low J.A, Phase 1 study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractoryacute leukemias and aggressive myeloproliferative disorders, Leukemia Research, January 2008; 32(1): 71-7.

Bashey A, Donohue M, Lin L, Medina B, Corringham S, Ihasz A, Carrier E, Castro J, Holman P, Ronghui X, Law P, Ball E, Lane T., Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-simulating factor and granulocyte- colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation, Transfusion, 2007 Nov; 47(11): 2153-60.

Mielke S, Rezvani K, Savani B, et al., Reconstitution of foxp3+ regulatory T cells (Tregs) after CD25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease (GvHD), Blood, 2007 Sep; 110:1689-97.

Baek W, Bashey A, Sheean G., Complete remission induced by rituximab in refractory, seronegative, muscle specific, kinase-positive myasthenia gravis, J Neurol Neurosurg Psychiatry, 2007, July;78(7): 771.

Matthews RH, Emami M, Connaghan DG, Holland HK, Morris LE., Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation, Bone MarrowTransplantation, 2007 Apr;39(7): 397-400.

Lancet J, Gojo I, Gotlib J, Feldman E, Greer J, Liesveld J, Bruzek L, Morris L, et.al, A Phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia, Blood, 2007 Feb15; 109(4):1387-1394.

Kebriaei P, Isola L, Bahceci E, Holland HK, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Uberti J. 306: Successful phase II trial using Mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft-vs-host disease (aGVHD), Biology of Blood and Marrow Transplantation, 2007 Feb;3(2): 111.

Anagnostopoulos A, Hari P, Perez W, Ballen K, Bashey A, Bredeson C, Freytes C, Gale R, Gertz M, Gibson J, Goldschmidt H, Lasarus H, McCarthy P, Reece D, Vesole D, Giralt S., Autologous or allogeneic stem cell transplantation in patients with Waldenstrom’s macroglobulinemia, Biology of Blood & Marrow Transplantation, 2006, Aug;12(8): 845-54.

Melenhorst JJ, Solomon SR, Shenoy A, et al., Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells, J Immunotherapy, 2006 Jul-Aug;29(4):436-43.

Bashey A, Liu L, Ihasz A, Medina B, Corringham S, Keese K, Carrier E, Castro JE, Holman P, Lane TA, Hassidim K, and Ball ED., Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged sixty or older, Leukemia Res., 2006, April;30(4): 503-6.

Tallman M, Perez W, Lazarus H, Gale R, Maziarz R, Rowe J, Marks D, Cahn J, Bashey A, Bishop M, Christiansen N, Frankel S, Garcia J, Llhan O, Laughlin M, Liesveld J, Linker C, Litzow M, Luger S, McCarthy P, Milone G, Pavlovsky S, Phillips G, Russell J, Saez R, Schiller G, Sierra J, Weiner R, Zander A, Zhang M, Keating A, Weisdorf D, Horowitz M., Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission, Biology of Blood & Marrow Transplantation, 2006, Feb;12(2): 204-16.

Montero A, Savani BN, Kurlander R, Read EJ, Leitman SF, Childs R, Solomon SR, Barrett AJ., Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning, British Journal of Hematology, 2005 Sep;130(5):733-9.

Gore SD, Smith DB, Gojo I, Morris LE, et al:, Durable molecular remission with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia, American Journal of Hematology, 2005 June; 79(2): 119 -127.

Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ,McCarthy P, et. al., Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients, Biology of Blood and Marrow Transplantation: 2005 May; 11(5): 389-98.

Solomon SR, Savani B, Montero A, et al., Improved Outcomes for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome, Biology of Blood Marrow Transplant 2005; 11:619-26.

Solomon SR, Mielke S, Savani BN, et al., Selective depletion of alloreactive donor lymphocytes- a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation, Blood, 2005; 106(3):1123-9.

Mielke S, Solomon SR, and Barrett AJ., Selective Depletion Strategies in Allogeneic Stem Cell Transplantation, Cytotherapy, 2005; 7(2):109-15.

Savani BN, Montero A, Wu C, Nlonda N, Read E, Dunbar C, Childs R, Solomon S, and Barrett AJ., Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation, Biology of Blood Marrow Transplant 2005; 11:223-230.

Karp J, Gojo I, Pili R, Morris LE, et al., Targeting vascular endothelial growth factor (VEGF) for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d- arabinofuranosylcytosine, mitoxantrone, and bevacizumab, Clinical Cancer Research, 2004 June1; 10(11): 3577-85.

Jacobsohn DA, Anders V, McMillan S, Morris LE, et al,Infliximab for the treatment of acute GVHD: A review and case series, American, Journal of Hematology, 2003 Oct; 74(2): 119-24.

Reece DE, Foon KA, Bhattarcharya-Chatterjee M, Adkins D, Broun ER, Connaghan DG, Dipersio JF, Holland HK, Howard DA, Hale GA, Klingemann HG, Munn RK, Raptis A, Phillips GL., Use of the anti- idiotype Breast Cancer Vaccine 11D10 in Conjuction with Autologous Stem Cell Transplantation in Patients with Metastatic Breast Cancer, Clinical Breast Cancer, 2003 Feb;3 Suppl 4: S152-7.

Reece DE, Foon, KA, Battacharya-Chatterjee M, Adkins D, Broun ER, Connaghan DG, Dipersio JF, Holland HK, Howard DS, Hale GA, Klingemann HG, Munn RK, Raptis A, Phillips GL., Interim Analysis of the use of the Anti-Idiotype Breast Cancer Vaccine 11D10 (TriAb) in conjunction with Autologous Stem Cell Transplantation in Patients with Metastatic Breast Cancer, Clinical Breast Cancer, 2001 Apr;2(1): 52-8.

Owen P, Connaghan DG, Holland HK, Steis RG., Bone Marrow Transplantation: Cancer therapy comes of age, Journal of Medical Association of Georgia, 1998 Apr;87(2): 145-6, 148.

Bomberger C, Singh–Jairam M, Rodney G, Guerriero A,Yeager AM, Fleming WH, Holland HK, Waller EK., Lymphoid Reconstitution Following Autologous PBSC Transplantation with FACS sorted CD34+ Hematopoietic Progenitors, Blood, 1998 Apr1;91(7): 2588- 600.